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The crosstalk between the Central Nervous System (CNS) and the immune system prompted the Neu-
roimmunology field towards the relevance of immune cells in supporting steady-state brain physiology. 
The recent (re)discovery of meningeal lymphatic vessels containing a wide repertoire of immune cells 
in the steady state that drain into the cervical lymph nodes established meninges as a strategic anatomical 
site for the neuroimmune interface.  
A pioneer publication from the host laboratory revealed an unexpected role for meningeal IL-17 in the 
regulation of short-term working memory and revealed a novel foetal thymic-derived population of me-
ningeal γδ T cell as the major source of IL-17 in the steady state CNS. Further studies highlighted the 
role of this cytokine in pathogen-avoidance behaviours and sociability. 
Notwithstanding, an IL-17 contribution to neuroinflammation is emphasized by its role during the de-
velopment and progression of experimental autoimmune encephalomyelitis (EAE) and brain ischemia 
upon injury. Furthermore, unpublished results from the host laboratory revel that exacerbated levels of 
meningeal IL-17 seemingly promote the onset of Alzheimer’s Disease (AD). IL-17-dependent acceler-
ated neurodegeneration was also reported in a Parkinson’s disease (PD) mice model. 
This suggests a dual role for IL-17 – pro-cognitive at steady state and anti-cognitive in the context of 
neurodegeneration – and implies a hypothetic meningeal IL-17 threshold, below which cognitive deficits 
would appear and above which pathogenic neuroinflammation would be triggered. Therefore, a fine-
tuned regulation of meningeal IL-17 homeostasis is seemingly required to maintain brain integrity and 
cognitive functions. 
Built on this background, this project aims to decipher the cellular and molecular mechanisms that 
control such an important - yet unexplored - process. Based on the literature and RNA-sequencing data 
from the host laboratory, we postulated a potential contribution of stress, circadian clock and sleep to 
meningeal IL-17 immune cell homeostasis in pathophysiological conditions. 
To test this hypothesis, we resorted to flow cytometry techniques to analyse the survival, proliferation 
and cytokine response of purified γδ T cells stimulated in vitro with different concentrations of gluco-
corticoids and in vivo glucocorticoid modulatory functions. Meningeal lymphocytes were also isolated 
from wild-type (WT) mice and from the 3xTg-AD mice model of AD for the characterization of IL-17 
diurnal oscillatory pattern. Finally, the effect of sleep on meningeal IL-17 was tested by anesthetizing 
mice through intraperitoneal injections of ketamine/xylazine (K/X). We observed an increased percent-
age, survival and proliferation of γδ T cells IL-17 producers (γδ17), the major contributor to IL-17 pro-
duction in the meninges, to glucocorticoid stimulation in vitro in a dose-dependent manner. However, 
no effect was observed in meningeal IL-17-producing cells after in vivo injection of glucocorticoids. 
Additionally, a diurnal oscillation of the percentage of meningeal IL-17-producing cells, with a mini-
mum during the light phase (bathyphase) and a peak during the dark phase (acrophase) was observed in 
WT mice. Conversely, the AD mice model and their littermate controls displayed no such oscillatory 
pattern. Our data also point at a reduction in meningeal IL-17-producing cells upon sleep. 
Although a stress contribution was not observed in vivo, our results suggest that circadian rhythms and 
sleep can regulate the homeostasis of IL-17-producing immune cells in the meninges. Importantly, both 
circadian clock and sleep are integrated systems that contribute to higher mental processes and neuro-
degenerative disorders. 
Taken together, this exploratory study is a further step towards the characterization of meningeal 
immune subset biology. The modulation of these cues might give further insight into the cellular and 
molecular mechanisms that underlie learning and memory with a biomedical potential for 
neurodegenerative diseases. 
 





Recentemente o campo da Neuroimunologia alargou o seu clássico foco patológico e entrou numa era 
focada nas implicações desta interação num contexto não inflamatório. A interação entre o sistema ner-
voso e o sistema imune durante o desenvolvimento, a vida adulta e o envelhecimento são importantes 
marcos a explorar que nos darão um vislumbre de questões desafiantes. 
A (re)descoberta dos vasos linfáticos meníngeos levou a uma reavaliação do conceito de cérebro como 
órgão imunologicamente privilegiado. Estudos recentes revelam que estes vasos linfáticos possuem um 
amplo repertório de células imunológicas qualificadas para monitorizar e proteger o sistema nervoso 
central (SNC) e influenciar as funções cerebrais através de moléculas solúveis, sem que ocorra infiltra-
ção no parênquima cerebral. 
Diferentes citocinas produzidas por células imunes a partir dos espaços meníngeos demonstraram um 
efeito surpreendente na modulação das funções cerebrais. Particularmente, a produção de IL-4 por cé-
lulas T CD4+ após a realização de tarefas cognitivas foi determinante na regulação da aprendizagem e 
memória a longo prazo. Uma recente publicação do laboratório de acolhimento demonstrou que a pro-
dução de IL-17 nas meninges, uma citocina frequentemente implicada em contextos inflamatórios, tem 
um papel surpreendente na regulação da memória de trabalho espacial de curto prazo através da modu-
lação da plasticidade sináptica no hipocampo. Esta publicação revelou ainda que uma nova população 
derivada do timo fetal – células T γδ – são a principal fonte de IL-17 no SNC saudável.  
Estes dados sugerem uma possível regulação diferencial de circuitos neuronais pelas diferentes citocinas 
presentes nos espaços meníngeos. A estas funções mediadas por IL-17 acrescem ainda as suas proprie-
dades neuromoduladoras envolvidas em comportamentos de evasão a patógenos e na promoção da so-
ciabilidade. Esta citocina emerge assim como novo ator em neurofisiologia. 
Apesar deste importante papel fisiológico, níveis exacerbados de IL-17 no SCN estão associados a morte 
neuronal e anomalias comportamentais. Para além disto, num contexto neuroinflamatório, a produção 
desta citocina por células T γδ tem um papel crucial no desenvolvimento de encefalomielite autoimune 
experimental (EAE) e na progressão de isquemia cerebral e défices neurológicos num modelo de lesão 
de isquemia-reperfusão (I/R) cerebral. Em ambos os modelos, as células T γδ produtoras de IL-17 (γδ17) 
presentes nas meninges desencadeiam um ciclo de amplificação imunológica local que irá alterar o mi-
croambiente estromal do cérebro inflamado e causar ruturas na barreira hematoencefálica que contribui-
rão para a progressão da doença. 
Resultados do laboratório de acolhimento demonstram ainda que num contexto neurodegenerativo, a 
produção exacerbada de IL-17 por células T γδ nas meninges está associada ao desencadeamento dos 
défices cognitivos observados num modelo de ratinho da doença de Alzheimer (3xTg-AD). A neutrali-
zação desta citocina foi suficiente para prevenir os défices da memória de trabalho espacial de curto 
prazo e disfunção da plasticidade sináptica observados nas fases iniciais da doença. Concentrações ele-
vadas de IL-17 no SCN estão ainda associadas à promoção da neurodegeneração num modelo de ratinho 
da doença de Parkinson. 
Estes dados sugerem um duplo papel da IL-17 no SCN. Enquanto a produção desta citocina em condi-
ções fisiológicas é indispensável para as funções cognitivas, a sua produção exacerbada contribui para 
a propagação da neuroinflamação e neurodegeneração. Isto implica um limiar hipotético ideal da con-
centração de IL-17 nas meninges, abaixo do qual surgiriam défices cognitivos e acima do qual se veri-
ficaria um desencadeamento de processos neuroinflamatórios. Assim, o controlo rigoroso da concentra-
ção desta citocina nas meninges parece indispensável para manter a integridade cerebral e as funções 
cognitivas. 
Com essa ideia em mente, este estudo exploratório tem como objetivo desvendar possíveis mecanismos 
homeostáticos que, em condições fisiológicas, regulariam diferentes produtores imunes de IL-17 




mecanismos poderá potencialmente contribuir para a acumulação desta citocina observada nas doenças 
neuroinflamatórias. 
Stress, ritmos circadianos e sono são processos com importantes implicações na modulação das respos-
tas imunes e cerebrais em contextos patofisiológicos. Considerando os dados da literatura, recorremos 
à análise de dados obtidos em ensaios de sequenciação de RNA realizados em diferentes populações de 
linfócitos T γδ isolados a partir de nódulos linfáticos periféricos. Estes dados permitiram observar que 
células T γδ produtoras de IL-17 (γδ17) sobreexpressam recetores de catecolaminas e glucocorticoides, 
assim como genes que codificam os principais reguladores dos ritmos circadianos, comparativamente 
com as populações de células T γδ produtoras de IFN-γ ou duplas negativas. 
Para testar uma potencial contribuição do stress na modulação das propriedades efetoras das células T 
γδ17, células T γδ totais ou as suas diferentes populações foram isoladas e colocadas em cultura com 
diferentes concentrações de glucocorticoides. Esta estimulação resultou num aumento da percentagem 
de células T γδ17 de forma proporcional à concentração, mediada pela estimulação da sua sobrevivência 
e proliferação. Estes dados corroboraram os resultados obtidos por sequenciação de RNA, ao sugerir 
que células T γδ17 são preferencialmente afetadas por glucocorticoides comparativamente com as res-
tantes populações. 
Para analisar uma possível contribuição do stress na modulação de células meníngeas produtoras de IL-
17 recorremos à injeção intraperitoneal de glucocorticoides in vivo. Surpreendentemente, não foi obser-
vado nenhum efeito significativo nos espaços meníngeos quatro horas após a injeção, embora uma mo-
dulação de células produtoras de IL-17 tenha sido observada em órgãos linfoides periféricos, corrobo-
rando os resultados obtidos in vitro. 
Para avaliar um possível envolvimento dos ritmos circadianos, células meníngeas foram isoladas de 
ratinhos em diferentes fases do dia para avaliar a produção de IL-17. Observou-se uma oscilação diurna 
da percentagem de células meníngeas produtoras de IL-17 que atingiu o seu valor mais baixo a meio do 
dia (batifase) e o seu valor mais alto durante a noite (acrofase). Estes dados indicam um potencial efeito 
dos ritmos circadianos na produção de IL-17 nas meninges. 
Considerando que as doenças neurodegenerativas estão geralmente associadas a distúrbios circadianos 
e a acumulação de IL-17 nas meninges está associada ao início dos défices cognitivos observados num 
modelo de ratinho da doença de Alzheimer, em seguida postulámos que estes distúrbios poderiam con-
tribuir para a acumulação de IL-17 verificada neste modelo que se traduziriam numa desregulação da 
oscilação diurna das células produtoras de IL-17 previamente observada. Inesperadamente nem os rati-
nhos controlo nem os ratinhos 3xTg-AD utilizados demonstraram uma oscilação diurna nestas células. 
Estes dados indicam que outras variantes como o contexto genético, idade ou sexo possam ter influen-
ciado os resultados obtidos. 
Considerando a interação entre os ritmos circadianos e o sono, em seguida postulámos que este último 
poderia regular a homeostase das células imunes produtoras de IL-17 das meninges. Para testar esta 
hipótese foi injetada uma solução anestésica de cetamina/xilazina que reproduz as principais caracterís-
ticas do sono e as células meníngeas foram isoladas uma hora e meia depois. Esta técnica permitiu-nos 
observar uma redução nas células produtoras de IL-17 nas meninges, sugerindo que o sono poderá ser 
outro mecanismo de regulação destas células em contextos fisiológicos.   
No seu conjunto, embora uma contribuição do stress não tenha sido observada in vivo, os nossos resul-
tados sugerem que os ritmos circadianos e o sono podem regular a homeostase das células imunes pro-
dutoras de IL-17 nas meninges. É importante destacar que estes dois processos estão fortemente interli-
gados e ambos contribuem para processos mentais superiores e distúrbios neurodegenerativos. 
Este estudo exploratório é assim mais um passo para a caracterização da biológica das células imunes 
meníngeas e, se validados, estes resultados poderão ter grandes implicações na manipulação da produção 




os conhecimentos sobre os mecanismos celulares e moleculares que fundamentam a aprendizagem e a 
memória com um potencial biomédico para doenças neurodegenerativas. 
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1.1 The Nervous System and the Immune System 
1.1.1 The Nervous System 
The nervous system is a complex, highly specialized network that is perceived as the command centre 
of the body1. In mammals, this system is anatomically divided in two main components: the central 
nervous system (CNS) and the peripheral nervous system (PNS)2. 
The structure and function of the CNS has been the focus of extensive research. In a simplistic way, the 
CNS can be divided into brain and spinal cord that will combine information and coordinate the response 
to environmental stimuli. Two main classes of cells are present: neurons – transporting information in 
the form of electrical impulses – and glial cells – mostly responsible for the support of neuronal cells. 
The signalling between these cell-types enables the different cognitive processes such as thinking, 
communicating, learning and memory storage2. 
The PNS conveys neuronal messages to and from the brain through the cranial and spinal nerves, 
connecting the CNS to the rest of the organism. Functionally, the PNS can be further divided into the 
somatic nervous system – associated with the voluntary control of movements – and the autonomic 
nervous system – responsible for the involuntary body functions and homeostasis maintenance3,4. The 
constant interaction between these two systems allows a continuous monitoring of the internal and 
external environmental cues, providing an adaptive advantage to the organism. 
1.1.2 The Immune System 
The immune system consists in a complex network of different organs, cells and proteins that work 
together to protect the human body from pathogens, including bacteria, viruses, parasites and fungi, as 
well as environmental and physiological perturbations that could disrupt tissue homeostasis and induce 
malignant changes5. The crucial role of the immune system for health and survival is emphasized when 
its function is impaired, resulting in inflammatory diseases, such as autoimmunity and cancer6. The 
immune response is driven by two main branches: the innate and the adaptive systems7. 
The innate system is considered the first defence barrier present in primitive animals and invertebrates. 
It is composed by granulocytes, monocytes, macrophages, dendritic and natural killer (NK) cells, short-
lived cells that respond immediately to a wide range of pathogens with relatively poor diversity of 
antigen (Ag)-specific recognition elements. In contrast, the adaptive system shows a delayed response 
but performs specialized responses by generating long-lived, Ag-specific cells after a first exposure to 
pathogens, while maintaining tolerance to self-constituents. The latter is present in more complex 
animals, including humans7 and its ability to create immunological memory results in a faster and more 
efficient response to subsequent encounters with specific pathogens. The adaptive immune system 
comprises both humoral immunity - mediated by antibodies (Abs) and antibody-secreting B cells (also 
known as plasma cells), that protect the human body against extracellular pathogenic agents and toxins 
– and cell-mediated immunity – composed mainly by T cells that work primarily against intracellular 
pathogens and cancerous cells. A precise orchestration of these two systems is fundamental to achieve 
maximum protection for the organism8.  
To ensure tissue homeostasis, a strict balance must be maintained between the detection of potentially 
harmful factors and the resolution of immune responses that, if unrestrained, lead to massive damages9. 
1.1.3 Neuro-immune crosstalks  
The blooming field of neuroimmunology studies the bidirectional interaction between the nervous and 
the immune system, both under homeostatic and pathological conditions10,11. These two systems, 
assumed to work in an independent manner for decades, form elegant bidirectional brain–immune 




during non-physiological events: an acute mental or physical stressor that activates the CNS can also 
induce an inflammatory response, while a microbial challenge that activates the immune system will 
prompt neurobehavioral, neuroendocrine and autonomic nervous system (ANS) responses12. 
Notwithstanding, the classical dogma of cytokines as immune communicator molecules and 
neurotransmitters as neuronal communicators is fading. Neurons and immune cells share intercellular 
signals and their respective receptors13. Cytokines participation in normal CNS function ranges from the 
regulation of sleep14, a variety of neuroendocrine functions15 and neuronal development16 to a possible 
implication in ageing17. On the other hand, immune cells contain the molecular machinery required to 
respond to neural factors including receptors for neurotransmitters18, neuropeptides19, hormones20 and 
the components of their signalling pathways21, but also the ability to synthesize and store 
neurotransmitters22. The nervous system-mediated regulation of immunity can occur through systemic, 
regional, or local routes21 with important implication for the development, homeostasis and functions of 
immune cells4. Within the several neuronal factors involved in the modulation of immune cell responses, 
a fundamental role for the PNS and the neuroendocrine modulation of immunity at a systemic level by 
the hypothalamic–pituitary–adrenal (HPA) axis must be acknowledged21. The effects of these neuronal 
factors will differ according to the time course of an immune response or the stage of immune-cell 
maturation23,24. 
The neuroimmune crosstalk provides a mean to optimize the effectiveness of the immune response and 
an enhanced preparation for an upcoming danger by synchronizing behaviour, metabolism and immune 
activity, increasing the potential for survival. Additionally, a faster homeostatic restoration will be 
achieved following pathogenic attacks, development of malignant cells or tissue damage25. 
1.2 Immune surveillance in the CNS 
The body’s most complex system requires exceptional protection1. As such, the skull and the vertebral 
column constitute the CNS primary protective layer against external damages and the blood-brain barrier 
(BBB) controls the communication with the periphery at an internal level26. Another level of protection 
is given by the meninges, a triple-layered membrane that comprises the dura mater (adjacent to the 
skull), the arachnoid mater and the pia mater (adjacent to the brain and spinal parenchyma) (Figure 
1.1A). The dura mater consists in a dense, collagenous, highly innervated and vascularized membrane. 
The arachnoid mater is a non-vascularized layer that regulates the transport of molecules. It encloses the 
sub-arachnoid space filled with cerebrospinal fluid (CSF) produced by the choroid plexus epithelium, 
which provides a mechanical barrier against shock and maintains a constant pressure within the 
cranium27. Within this space, thin projections called trabeculae extend into the pia mater, a highly 
vascularized layer composed of permissive flat cells adherent to the CNS parenchyma surface. Together, 
the arachnoid and pia mater form the leptomeninges. Juxtaposed to the pia mater, the glia limitans 
composed of astrocytic endfeet form a dense membrane of selective permeability28,29. 
The CNS critical role for survival and its limited regenerative capacity led to the long-lasting concept 
of the brain as an immune-privileged organ30,31. This view was mostly supported by the prolonged 
survival of homologous tissues grafted into the brain30 and the presence of immune cells in the CNS 
parenchyma was perceived as a hallmark of neuropathology10. However, recent studies have revealed 
that the CNS is neither isolated nor passive in its interactions with the immune system32,33. Rather, 
constitutive immune surveillance is provided by cells patrolling around and residing within the CNS9. 
Despite the limited access, the brain parenchymal tissue comprises resident microglia with fundamental 
roles in brain homeostasis throughout life and in disease contexts34. 
This new concept was also supported by the recent (re)discovery of meningeal lymphatic vessels. 
Although first described in the eighteenth century35, only recently a definite structural and functional 
characterization of meningeal lymphatic vessels was provided in mice26,36–38 and humans39. The 




active organ as the brain requires a constant drainage to prevent the accumulation of potentially toxic 
compounds and ensure a correct performance40. This conventional and functional lymphatic system 
located parallel to the venous sinus in the dura mater provides, for the first time, a direct link between 
the brain parenchyma and the periphery41 (Figure 1.1A). Its privileged location allows the continuous 
drainage and clearance of fluid, macromolecules and immune cells from the brain into the deep cervical 
lymph nodes (dcLNs) and later to the superficial cervical lymph nodes (scLN)38,41,42. 
Through the glymphatic route, the CSF is prompt into the brain by arterial pulsation through aquaporin-
4 (AQP4) water channels of the astrocytic end feet of glia limitans, creating a convective bulk flow of 
brain interstitial fluid  (ISF) that allows an exchange of neurotransmitters, hormones, proteins, 
cytokines, antigens and waste products43,44. Impairments in this cleaning route have harmful 
consequences for brain physiology40. The identification of meningeal lymphatic vessels as a cleaning 
route of CSF content highlighted its importance for brain CNS physiology37,45. 
 
Figure 1.1 - Steady state meningeal anatomy and immune composition. (A) Meningeal lymphatics are located parallel to 
the venous sinus in the dura mater, follow the transverse sinus until the base of the skull to form the basal lymphatics and 
surround the cerebellum. The CSF is produced in brain ventricles, fills the subarachnoid space and can be drained via meningeal 
lymphatics toward the dcLNs. [Extracted from Alves de Lima, K. et al., Annual Review of Immunology 202028] (B) Schematic 
representation of the three meningeal membranes, the dura, arachnoid and pia maters. The latest forms the final barrier before 
the parenchyma, restricting the diffusion of molecules to 3 kDa. [Extracted from Rua, R., & McGavern, D. B. Trends in 
Molecular Medicine 201829] 
Importantly, a progressive dysfunction of meningeal lymphatic vessels is observed with age. The 
disruption of meningeal lymphatic function in young-adult mice impairs the macromolecule removing 
from the interstitial fluid to the dcLNs and recapitulates the learning and memory deficits observed 
during aging46. Treatment of old mice with recombinant vascular endothelial growth factor C (VEGF-
C) improved the drainage of CSF macromolecules and cognitive function37,46, through a VEGF-C-
dependent increase of the diameter of meningeal lymphatic vessels42. Additionally, the induction of 
meningeal lymphatic disfunction in mouse models of Alzheimer’s disease (AD) worsened amyloid-β 
(Aβ) pathology in the meninges and in the brain46. 
1.2.1 Impact of Meningeal Immunity on Neurophysiology 
Under steady state conditions and in opposition to the brain parenchyma (apart from the choroid plexus), 
meninges are populated by many different immune cell populations (e.g., macrophages, dendritic cells 
(DCs), innate lymphoid cells (ILCs), mast cells, neutrophils, B cells and T cells) (Figure 1.1B). Due to 
their strategic location at the interface between the periphery and the brain, the meninges function as the 
first line of protection of the CNS and represent a major site of immune cell residency and recruitment29. 





before entering the dcLN where they can be primed47,48. All these features establish the meninges as a 
unique and complex microenvironment, with the potential to regulate brain homeostasis. 
The role of immune cells to guarantee CNS functions and homeostasis has become indisputable26. T 
cells emerged as protagonists that contribute to physiological brain functions49, including sensory 
responses50, stress responses51 and adult neurogenesis52. Since these cells do not penetrate the brain 
parenchyma at steady state53, their effects are seemingly mediated through the secretion of soluble 
factors from the meninges49,54. Remarkably, reports of severe combined immune-deficient (SCID) mice 
impaired ability to perform spatial learning and long-term memory tasks, along with defective adult 
neurogenesis, turn a new leaf in the comprehension of cognition and behaviour55,56. It was latter 
demonstrated that the underlying mechanism was cluster of differentiation (CD)4+ T cell dependent47,57. 
More specifically, T cell derived interleukin (IL)-4 production after engaging in learning/long-term 
memory tests enhances the production of glial neurotrophic factor58. This study showed, for the first 
time, the importance of the cytokine content of the meningeal milieu for brain physiology. Another 
important finding concerning meningeal immunity participation in neuronal functions and complex 
behaviours was the observation of a deficient social behaviour in SCID mice. Similarly, interferon 
(IFN)-γ-deficient mice also exhibited social deficits and the repopulation of SCID mice with T cells or 
injections of IFN-γ could restore social interactions. This reveals IFN-γ as a molecular link between 
meningeal immunity and neural circuits, necessary for social behaviour59. 
1.3 IL-17: A Central Player in Pathophysiology 
IL-17A, generally called IL-17, is a pro-inflammatory cytokine highly conserved across the evolution 
of the vertebrate immune system and part of a family composed of six members — from IL-17A to 
IL-17F. IL-17A and IL-17F share the highest structural identity and are the main IL-17 family members 
that contribute to host defence against extracellular bacterial and fungal pathogens. The IL-17 receptors 
(IL-17R) family is composed of 5 receptors - IL-17RA, IL-17RB, IL-17RC, IL-17RD and IL-17RE. 
IL-17A and IL-17F bind to the heterodimeric receptor complex composed of IL-17RA and IL-17RC 
subunits. In the presence of the adaptor protein Act1 and tumour necrosis factor receptor-associated 
factor 6 (TRAF6), IL-17A and/or IL-17F canonical signalling will activate the nuclear factor-κB (NF-
κB) and mitogen-activated protein kinase (MAPK) and CCAAT-enhancer-binding protein path-
ways60,61, leading to downstream target genes activation. IL-17 is a potent inducer of inflammation and 
its effects are mediated via the recruitment of immune cells such as neutrophil and monocytes, anti-
microbial peptide secretion and complement responses to stimulate epithelial barrier function60,62. An 
active involvement in immune cell recruitment is accomplished by an induction of proinflammatory 
cytokines and chemokines, and matrix metalloproteinase (MMP) production that, in turn, will create a 
positive feedback loop that enhances the production and strengthens the effects of IL-1763,64. Among its 
epithelial protective roles, IL-17 is involved in the maintenance of intestinal barrier integrity through 
the regulation of claudins, main components of tight junctions, and antimicrobial peptides65. 
Different cellular sources of IL-17 have been discovered over the years. The observation that CD3+ T 
cell receptor (TCR)αβ+ CD4+ cells require different cytokines and transcription factors to produce IL-17 
than those involved in the development of the classic type 1 and type 2 T cells (TH1 and TH2 cells, 
respectively), led to the discovery of the new TH17 subset66,67. This subset requires IL-6 and tumour 
growth factor (TGF)-β67 to differentiate from naive T cells, with potentiating effects from the combina-
tion of IL-1β and tumour necrosis factor (TNF); IL-21 and TGF-β; and IL-6, IL-1β and IL-2363,64,68. 
Besides TH17, several other immune cell types can produce IL-17 which share IL-23R and CCR6 surface 
expression, and have retinoic orphan receptor (ROR)t as their master transcription factor that is both 




CD3+TCRγδ+ γδ T cells, CD3+NK1.1+ NKT cells, CD3-NK1.1+ NK cells and CD3− ILC3s63. Addition-
ally, CD3+TCRαβ+CD8+ cells, CD3+CD4−/+CD8− mucosal-associated invariant T (MAIT) cells, 
KIT+LIN– lymphoid-tissue inducer (LTi)-like and myeloid cells have also shown to produce IL-1770–72. 
A major source of IL-17 in steady-state tissue physiology is provided by γδ T cells, a particular subset 
that blend innate and adaptive immune cell functions – termed as an “adaptate” biology73. These cells 
acquire their effector functions during thymic development and their activation is typically independent 
of antigen presentation by major histocompatibility complex (MHC) molecules74, unlike αβ CD4+ T 
cells that mostly leave the thymus as ‘naive’ cells75. γδ T cells are able to sense and respond immediately 
to infections or non-microbial stress without the need of clonal expansion or de novo differentiation76. 
Critically, this places them as the first line of defence that precedes antigen-specific αβ T cell re-
sponses76. For instance, γδ T cell-derived IL-17 is fundamental for the early response to Mycobacterium 
tuberculosis pulmonary infection77. Additionally, dendritic epidermal γδ T cells (DETCs) IL-17 produc-
tion in critically involved in wound healing by the promotion of multiple host-defence molecules in 
epidermal keratinocytes78 and in the protective response to UV radiation through the stimulation of de-
oxyribonucleic acid (DNA) repair79. Beside host defence, γδ T cell-derived IL-17 has crucial functions 
in (non-barrier) tissue physiology. By instance, an important homeostatic control of body temperature 
is exerted in the adipose tissue via IL-17A and TNF. The production of IL-33 in response to these cyto-
kines by adipose stromal cells is fundamental to the maintenance of regulatory T cells (Tregs) and for 
the metabolic adaptation to cold temperatures80. Interestingly, it was later described that IL-17F, not IL-
17A, was crucially involved in thermogenesis by the promotion of sympathetic innervation through a 
mechanism partly mediated by TGFβ expression in adipocytes81. Additionally, IL-17A-producing γδ 
(γδ17) responses are involved in skeletal tissue regeneration. The stimulation of proliferation and oste-
oblastic differentiation of mesenchymal progenitor cells by IL-17A accelerates osteoblastic bone for-
mation and aids fracture healing82. 
1.3.1 Pathophysiological implications of IL-17 in the CNS 
Inspired by important reports of an immune cell support of brain physiology, a pioneer publication from 
the host laboratory revealed an unexpected role for meningeal IL-17 in the regulation of short-term 





Figure 1.2 – Steady state meningeal γδ17 promote short-term working memory. The production of IL-17 in the meningeal 
spaces by γδ T cells induces the production of brain-derived neurotrophic factor (BDNF) by glial cells that promotes hippo-
campal synaptic plasticity, a fundamental process to spatial learning and memory formation. [Adapted from Ribeiro, M. et al., 
Science Immunology 201953] 
When tested in the Y-maze (a classical paradigm to analyse short-term working memory), animals de-










analysis of meningeal immune cell populations of WT mice revealed a novel foetal thymic-derived pop-
ulation of meningeal γδ T cell as the major source of IL-17 (γδ17) in the steady state CNS. At the 
functional level, IL-17 promotes learning and memory by favouring the glutamatergic synaptic plasticity 
of hippocampal neurons. This effect was mediated brain-derived neurotrophic factor (BDNF) produc-
tion by glial cells53 (Figure 1.2). Importantly, this study added an innate like population - γδ T cells - to 
the repertoire of immune populations infiltrating the CNS that regulate neurophysiology. 
Further studies have reported a role for IL-17 in brain physiology. IL-17 direct action on Caenorhabditis 
elegans neurons regulates pathogen-avoidance behaviour through a potentiation of circuit function83. 
Furthermore, in a mouse model of maternal immune activation (MIA), the activation of IL-17RA+ neu-
rons in the CNS rescued the sociability behaviour deficits exhibited by these mice84.  
Conversely, IL-17 has been shown to promote neuronal death and behavioural abnormalities. IL-17 was 
found to negatively regulate adult neurogenesis in the dentate gyrus (DG) of the hippocampus under 
physiology conditions85. Moreover, maternally derived IL-17 action on the developing fetal brain me-
diates an autism-like phenotype in the offspring86. The risk of neurodevelopmental disorders in the off-
spring increases with the presence of gut microbiota-dependent inflammatory IL-17 in pregnant moth-
ers87.  Additionally, an important contribution of IL-17 to neuroinflammation and neurodegenerative 
diseases is under the spotlight. Using non-physiological stimuli, IL-17 demonstrated to be involved in 
lipopolysaccharide (LPS)-induced systemic inflammation, consequently promoting neuroinflammation 
and memory impairments via microglial activation88. In a mouse model of cerebral ischemia-reperfusion 
(I/R) injury, IL-17 has a pivotal role in the progression of brain infarction and neurological deficits, with 
γδ T lymphocytes as the major source of this cytokine89. This subset was shown to be regulated by 
intestinal dysbiosis and a microbiota–γδ17 T cell–brain axis was identified, having meninges as the 
preferential destination90. Furthermore, a crucial role for IL-17 in the development of experimental au-
toimmune encephalomyelitis (EAE), a mouse model for multiple sclerosis (MS), is evidenced by the 
delayed onset, reduced severity and early recovery of EAE induced in IL-17–/– mice91. Also in this con-
text, γδ T cells are an important source of IL-17 that will then mediate the recruitment of IL-1β-secreting 
myeloid cells that prime pathogenic γδ17 and T helper (TH)17 cells92,93. In both I/R injury and EAE 
pathology, γδ17 T cells in the meningeal spaces unleash a local immune amplification loop that will 
alter the stromal microenvironment of the inflamed brain, cause BBB disruptions and ultimately con-
tribute to disease progression94,95. Interestingly, clinical studies in patients support a pathogenic role of 
IL-17 by reporting an increased amount of this cytokine in the brain, blood and CSF of stroke96,97 and 
MS patients98,99. 
Last but not least, a pathogenic role for IL-17 in a neurodegenerative context has also been sug-
gested100,101. Unpublished work from the host laboratory reveals an exacerbation of IL-17 levels in the 
meningeal compartment of a progressive mouse model of AD (3xTg-AD) at the onset of cognitive de-
cline (5-6 months of age), mainly provided by γδ T cells (Figure S1). Critically, IL-17 neutralization 
with anti-IL17 monoclonal Abs (mAbs) was sufficient to prevent short-term reference memory deficits 
and synaptic plasticity dysfunction observed at early stages of disease (Brigas, H. et al., under review). 
Additionally, using a genetically modified progressive mouse model of Parkinson’s disease (PD) char-
acterized by an overexpression of human alpha-synuclein (αSyn) (Thy1-αsyn mice), we observed a pu-
tative accumulation in meningeal IL-17 levels in transgenic mice compared with littermate controls, at 
6-months of age (Figure S2). At this stage of disease, Thy1-αsyn mice display impaired coordinated 
motor tasks102 that are dependent on gut microbial colonization and exacerbated with gut dysbiosis103, 
and exhibit memory and synaptic impairments104. As observed in the 3xTg-AD, this cytokine was 
mainly provided by γδ T cells, implying a homeostasis dysregulation of γδ17 T cells in the meninges in 
pathological settings. Concomitantly, a pathogenic role for IL-17 has also been suggested in a model of 
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced PD, contributing to BBB disruption, 




these findings support the idea of a dual role for IL-17 in physiological versus pathological conditions. 
Whereas at steady state the production of IL-17 by meningeal γδ T cells is fundamental to ensure learn-
ing and memory, its exacerbated production upon inflammation contributes to the pathogenesis of neu-
roinflammation53. Therefore, a tight control of meningeal IL-17 homeostasis is required to maintain 
brain integrity and cognitive functions. Based on data from the literature, we hypothesize that neuro-
modulators, circadian rhythms and sleep might contribute to this control. 
1.4 Potential Mechanisms Regulating Meningeal Immunity 
1.4.1 Stress 
Stress is a natural and fundamental physiological response that prepares the organism for an upcoming 
challenge106. During a stressful event, the amygdala will send distress signals to the hypothalamus, 
perceived as the command centre of the body. This leads to the activation of the sympathetic nervous 
system (SNS) that releases catecholamines, such as norepinephrine and adrenaline, triggering a “fight-
or-flight” response107,108. Additionally, the activation of the HPA axis (Figure 1.3) will orchestrate and 
synchronize complex physiological processes through changes in the internal and external environments 
mediated by hormones. Upon exposure to a stressor, the secretion of corticotrophin-releasing hormone 
(CRH) and arginine vasopressin (AVP) by the hypothalamus will induce the secretion of 
adrenocorticotropic hormone (ACTH) by the anterior pituitary gland. Circulatory ACTH will stimulate 
the adrenal cortex to produce glucocorticoids - cortisol in humans, corticosterone in rodents -, the final 
product of the HPA axis. In addition to stress, a constant regulation of the HPA axis is provided by the 
circadian clock in steady state conditions109,110. Consequently, a peak of glucocorticoids anticipates 
wakening and the activity cycle: early morning in diurnal and early night in nocturnal animals111. 
 
Figure 1.3 - Regulation of glucocorticoid production by the hypothalamic–pituitary–adrenal axis. Glucocorticoid 
production is an autoregulated process that depends on hypothalamic activation by several endogenous and exogenous cues 
(such as stress, circadian cues and cytokines) that results in the production of corticotropin-releasing hormone (CRH) and 
arginine vasopressin (AVP). These hormones stimulate secretion of adrenocorticotropin hormone (ACTH) that induce the 
steroidogenic process using cholesterol. Glucocorticoids can control their own synthesis by acting on the hypothalamus, 
pituitary gland or on the immune system. [Extracted from Cain, D. W. & Cidlowsji, J. A. Nat. Rev. Immunol 2017109] 
Glucocorticoids will exert their functions by binding to the glucocorticoid receptors (GRs) that are 
encoded by the Nuclear Receptor Subfamily 3 Group C Member 1 (Nr3c1) and spread throughout the 
body. Glucocorticoid secretion will induce a negative feedback loop due to the activation of GRs 
expressed by cells in the hypothalamus and pituitary gland109. Furthermore, an immune regulation of 
glucocorticoid production is exerted by the direct activation of Toll-like receptors (TLRs) expressed in 
human and mouse adrenals112,113. During bacterial infections TLRs activation directly induces 
adrenocortical steroid release, enabling the body to immediately respond to external and internal stimuli 
with an efficient endocrine response. Pro-inflammatory cytokines, such as IL-1, TNF114 and IL-6115 also 
have modulatory effects on the HPA axis. The release of these cytokines during inflammatory events 
results in the direct activation of the hypothalamus and pituitary inducing CRH and ACTH release and, 
consequently, corticosteroid production116. This HPA-axis immune control provides a second feedback 




as potent neuromodulators. Thus, a crosstalk between the endocrine and the immune systems is 
fundamental for the control of inflammatory responses. 
1.4.1.1 Stress and Immune Function 
Although often seen as noxious, stress effects will differ according to the duration, intensity and 
chronicity117. An acute stress response triggers immune responses118 by enhancing leukocyte circulation 
to the blood and infiltration to inflamed tissues, as well as by promoting the proliferation and functions 
of several immune populations119–121. On the other hand, chronic stress is often associated with 
immunosuppressive effects and higher risk of infection illnesses122. Increased levels of pro-
inflammatory genes, decrease in genes involved in innate antiviral responses and antibody synthesis123, 
accumulation of pro-inflammatory leukocytes124, a shift towards a type 2 immune response which is 
associated with an increased susceptibility to autoimmune disorders125 and restructure of lymphatic 
networks within and around tumours to provide pathways for tumour cell escape126 are some of the 
described effects of chronic stress25. 
Owing to the innervation of primary and secondary lymphoid organs by sympathetic nerves127, the PNS 
exert important roles through the release of catecholamines and neuropeptides4. For instance, these 
signals are involved in haematopoiesis regulation through hematopoietic stem cell (HSC) retention in 
the bone marrow (BM)128,129 and in adaptive cell priming in the lymph nodes (LNs) through dendritic 
cell (DC) regulation130,131. Additionally, a modulation of immune cell trafficking is achieved through a 
physical interaction of β2-adrenergic receptors (β2ARs) with the chemokine receptors C-C chemokine 
receptor type 7 (CCR7) and chemokine receptor C-X-C chemokine receptor type 4 (CXCR4) expressed 
on lymphocyte surface that inhibits their egress from the LNs132. Furthermore, a diurnal lymphocyte 
recirculation through LNs controlled by the adrenergic nerves has important implications for the 
adaptive immune response efficiency133. On the other hand, glucocorticoids released from the adrenal 
cortex are mainly perceived as immunosuppressive and anti-inflammatory109,122. Accordingly, synthetic 
glucocorticoid agonists, such as dexamethasone, are used in several inflammatory conditions, including 
multiple sclerosis and asthma134,135. Glucocorticoid signalling can exert potent regulatory effects on 
cellular immunity136 by negatively affecting DC activity137, as well as T cell development, activation, 
cytokine production, polarization and survival138. Importantly, dysregulation the HPA axis induced by 
chronic life stress during prenatal life can determine the permanent reprogramming of the 
neuroendocrine stress pathway139 that results in reduced glucocorticoid levels in adults, leading to 
attenuated anti-tumour and antibacterial CD8+ T cell responses140. It was recently shown that Tregs are 
direct targets and key players of glucocorticoid anti-inflammatory effects141. Last but not least, a recent 
study reports that glucocorticoids influences diurnal oscillations of T cell survival and distribution 
among lymph nodes, spleen, and blood by modulating the expression of interleukin-7 receptor (IL-7R) 
and CXCR4 on T cells, thus contributing to differential (diurnal) responses against pathogenic insults142. 
1.4.1.2 Stress in Brain Pathophysiology 
Glucocorticoids are involved in the consolidation of memories during emotional stressful events143, by 
diffusing into the brain and binding to the GRs expressed in most brain regions, namely in hippocampal 
CA1 neurons144,145. Since the hippocampus is fundamental for the formation of spatial and episodic 
memory, glucocorticoid can easily modulate this process143 and circadian glucocorticoid peaks have 
shown a fundamental role in the stabilization of newly formed spines that are important for long-term 
memory retention146. Notwithstanding, excessive levels or long-term exposure to glucocorticoids can 
have hazard effects147. While acute stress enhances synaptic plasticity and facilitates spatial learning by 
an increase in glutamate release, chronic stress is a major risk factor for accelerating the onset of mental 
health disorders148,149. By instance, chronic exposure to glucocorticoids eliminates this learning-




glucocorticoid dysregulation increases the offspring’s risk of developing psychiatric disorders in 
humans later in life150, such as autism spectrum disorder (ASD)151, depression152, anxiety153, amongst 
others, with more profound effects if maternal exposure to prenatal GCs occurs out of circadian 
phase/time of the day154. Of note, blockage of GR signalling can attenuate post-traumatic behavioural 
deficits induced after stress exposure, by enabling the recruitment of Gata3- and Foxp3-expressing 
T cells to the brain155.  In human, the importance of stress for brain physiology is evidenced by Cushing 
syndrome and Addison’s disease, that are associated with high levels or low levels of corticosterone, 
respectively. Both conditions present severe psychological in addition to physiological symptoms. 
Altogether, this glucocorticoid-regulated neuroendocrine stress axis shows fundamental implications for 
brain physiology. 
1.4.2 Circadian Rhythms 
The circadian system comprises a set of endogenous autonomous oscillators that modulate the physio-
logical activities of different tissues according to the 24-hour periodicity in the Earth’s rotation, provid-
ing an adaptive advantage to organisms156. In this system, the suprachiasmatic nucleus (SCN) in the 
anterior hypothalamus is the master pacemaker that oscillates autonomously in response to several en-
vironmental cues or “zeitgebers” (ZTs) (Figure 1.4A). The main entrainment pathway of this system 
are photic cues (the light/dark cycles) processed through the eye and transmitted via the retinohypotha-
lamic tract (RHT) to neurons of the SCN157,158. As an output, synchronizing signals will regulate the 
oscillation of the peripheral clocks present in most (if not all) cells throughout the body to coordinate 
tissue-specific rhythms159. This synchronization is maintained by a combination of neuronal signalling, 
secretion of hormones and metabolic cues provided by rhythmic feeding behaviour160.  
          
Figure 1.4 – The circadian clock in mammals. (A) The light/dark cycles received via the retinohypothalamic tract (RHT) 
synchronize the SCN that coordinates the circadian oscillations of several clocks within the brain (that regulate sleep, appetite, 
feeding behaviour, cognition, mood, etc.) and the periphery (that regulate blood pressure, triglyceride metabolism, renal func-
tion, etc.) through neuroendocrine and autonomic signalling. [Extracted from Hastings, M. H., Maywood, E. S. & Brancaccio, 
M. Nat. Rev. Neurosci. 2018158] (B) The molecular clock comprises several transcriptional–translational feedback loops that 
include positive (red), negative (yellow) and stabilizing (blue) elements. The final product of this regulation is a rhythmic 
expression of circadian-clock-controlled genes (CCGs) that will control complex physiological processes throughout the body 
according to several environmental cues. [Extracted from Kondratova, A. A. & Kondratov, R. V. Nat. Rev. Neurosci. 2012161] 
At the molecular level, these rhythms result from complex circadian transcription–translation feedback 
loops (Figure 1.4B). The main loop takes 24h to be completed and is comprised by the core clock 
proteins: Brain and Muscle ARNT-Like 1 (BMAL1) encoded by Arntl gene and circadian locomotor 
output cycles kaput (CLOCK) encoded by the Clock gene. The transcription and heterodimerization of 
BMAL1 and CLOCK drive circadian processes by inducing their own expression, the expression of 
negative regulators of this cycle, such as period circadian protein (PER) and cryptochrome (CRY), the 





members and their bind to canonical E-box sequences (CACGTG) in clock-controlled genes (CCGs). 
In this main loop, the PER–CRY complex will repress the binding of BMAL1–CLOCK to target genes 
until their own degradation occurs and the cycle starts anew. A second autoregulatory feedback loop is 
prompted by the REV-ERBα–REV-ERBβ complex that represses Arntl transcription158,159,161. 
This internal circadian clock controls all aspects of physiology, including sleep–wake cycles, behaviour 
and locomotor activity, body temperature cycles, cardiovascular and digestive processes, the endocrine 
system, metabolism and immune functions156. 
1.4.2.1 Circadian clock and Immune Function 
A circadian control of innate and adaptive immune cells is interpreted as a mechanism to enhance sen-
sitivity and immunosurveillance ahead of activity and feeding during the active phase, when the risk of 
infection would be highest162. For instance, administration of LPS during the active phase of mice sig-
nificantly reduces the mortality rate compared with administration during the resting period163. Accord-
ingly, in humans, the antibody response induced by vaccination is higher in the morning than in the 
afternoon164. These intrinsic timers can affect several features of the immune system. A fluctuation of 
lymphocytes in the blood and LNs was described as the result of a cell-intrinsic oscillation in trafficking 
molecules, such as adhesion molecules and chemokine receptors, and lineage- and tissue-specific oscil-
lations of promigratory factors, such as endothelial cell-adhesion molecules165. This results in a lympho-
cyte homing to LNs that peaks at the active phase onset and is affected by the modification of photic 
cues166. In addition to immune cell trafficking, circadian oscillations can also modulate the effector 
functions of group 3 innate lymphoid cells (ILC3s) reflected by Rorc, Il17a and Il22 diurnal oscillatory 
expression167. Circadian disruptions disturb ILC3s homeostasis in the gut which results in number and 
cytokine secretion reduction. This regulation is fundamental to ensure intestinal homeostasis, lipid me-
tabolism, microbiota composition and enteric defence against bowel infections induced by pathogenic 
bacteria168,169. Additionally, a circadian regulation of intestinal IL-17–producing CD4+ T helper (TH17) 
cells by the basic leucine zipper transcription factor nuclear factor IL-3-regulated protein (NFIL3) was 
described. Rhythmic expression of NFIL3 induced by the circadian clock protein REV-ERBα regulates 
TH17 cell frequency via the suppression of Rorc, which encodes RORγt, a key transcription factor nec-
essary for IL-17-producing cell differentiation170. 
Taking together, these reports emphasize the importance of a healthy intact clock for immune homeo-
stasis and the prevention of several pathologies. In fact, a negative impact of shift-work on health has 
been largely described171 and is associated with increased risk of cancer, obesity, heart disease, gastro-
intestinal dysfunction, sleep disorders, diabetes and depression172. 
1.4.2.2 Circadian Clock in Brain Pathophysiology 
Notably, the phase coherence between brain circadian clocks is critical for brain homeostasis, influenc-
ing several mental processes such as cognitive function, adaptation to novelty and mood161. By instance, 
cognitively complex tasks requiring short-term memory show a circadian rhythm dependence that peaks 
around midday in humans173. The potential mechanisms underlying the role of circadian rhythms on 
cognition and memory formation include synaptic plasticity174, neurogenesis175 and sleep176. 
Importantly, a link between circadian rhythm disruptions and the pathophysiology of neurodegenerative 
diseases can be anticipated. Since sleep and circadian rhythms disruption is one of the earliest and most 
common signs of neurodegenerative diseases - such as Alzheimer, Parkinson and Huntington’s diseases 
- that worsen with disease progression, a possible circadian clock control of neurodegeneration has been 
discussed161. In accordance, single nucleotide polymorphisms (SNPs) in Clock and Arntl are associated 
with increased susceptibility to AD, while SNPs in Arntl and Per1 are associated with PD177–179. Inter-
estingly, the deletion of REV-ERBα, a circadian clock component directly regulated by BMAL1, in-




neuroinflammation180. Within the potential mechanisms of circadian clock-dependent regulation of neu-
rodegeneration is the circadian control of the antioxidant defence181, of nucleotide excision repair sys-
tems182 and the regulation of autophagy activity183. Disruptions in the normal clock function may result 
in the failure of these brain cleaning systems followed by increased oxidative damage, reduced removal 
of DNA lesions, increased neuronal death and decreased autophagy, thus contributing to neurodegener-
ative diseases development161. 
1.4.3 Sleep 
Sleep is a physiological process regulated by a homeostatic process – that prolongs the sleep period 
according to the wakefulness duration – and the circadian system – responsible for synchronizing the 
propensity to sleep or be awake along the 24-h sleep-wake cycle, according to the two-process model 
of sleep regulation184. In mammals, the two core stages of sleep are the slow wave sleep (SWS) and the 
rapid-eye-movement (REM) sleep, which alternate in a cyclic manner. On an evolutionary perspective, 
the vital function of sleep is strengthened by its conservation across all species185. Indeed, this biological 
process is critical to ensure optimal brain and body health, given its implications in metabolism, appetite 
regulation and the functioning of immune, hormonal and cardiovascular systems186. Consequently, sleep 
deprivation is associated with cardiovascular diseases, obesity, diabetes and cancer187,188. 
1.4.3.1 Sleep and Immune Function 
During an inflammatory event, the induction of fatigue and sleepiness (among other symptoms) is trig-
gered by an immune system activation of the CNS, likely facilitating recovery12. It is not surprising that 
if the immune system can affect sleep, sleep can also cause major changes in the immune system re-
sponse189,190. Although the effects of sleep and the circadian rhythms are difficult to dissociate, it is 
known that the nocturnal period is characterized by a downregulation of the HPA axis and SNS, as well 
as an upregulation of pro-inflammatory signals like the growth hormone (GH), prolactin and melato-
nin191. Consequently, immune cell redistribution, activation, proliferation, differentiation and the pro-
duction of pro-inflammatory cytokines like IL-1, IL-12, TNF-α and of TH1 cytokines like IFN-γ is stim-
ulated, with beneficial effects for adaptive immunity13. In contrast, upon wakening, a rise of stress hor-
mones with potent anti-inflammatory potential is observed. This system optimizes immune cell function 
by boosting adaptive immune memory response during the resting time when destabilizing influences 
(stress or immunosuppressants) reach their minimum levels, while during the active time, the activity 
and stress support immediate cytotoxic effector functions against invading pathogens and tumour 
cells192. Such orchestration will avoid a competition for resources that will optimize these important 
physiological processes and allow coordination between the organism and the environment25. 
1.4.3.2 Sleep in Brain Pathophysiology 
Sleep contribution for memory formation and consolidation has long been recognized193. According to 
the synaptic homeostasis hypothesis, sleep enhances the strength of synapses formed during information 
acquisition in the prior awaken time194. Recently, another important role of sleep in the removal of toxic 
waste metabolites from the brain was described. During sleep, a 60% increase in the cortical interstitial 
space results in an increase on the convective exchange of CSF and ISF and the removal of interstitial 
toxic proteins resultant from neural activity that accumulate during wakefulness, including Aβ and Tau 
in mouse and humans185,195. Interestingly, this clearance route in under a circadian control, with the CSF 
drainage to the LNs exhibiting diurnal oscillations that are supported by the differential polarization of 
AQP4196. Consequently, sleep deprivations or disturbances have hazard consequences for cognition and 
emotions, reducing learning, impairing cognitive performance193, prolonging reaction time197, provoking 
seizures198 and promoting neurological diseases185,199. Extreme cases of sleep deprivation can also lead 




2. Aims of the Thesis 
An exciting new era for neuroimmunology is emerging and recent advances reshaped our understanding 
of meninges as gatekeepers that direct and coordinate immune traffic throughout the CNS29. In line with 
this, data from the host laboratory reported new clues on the evolutionary link between the immune and 
nervous systems, by revealing a previously unknown meningeal γδ T cell subset that produces IL-17 in 
the steady state CNS. This subset was shown to regulate short-term working memory, by enhancing 
neuronal synaptic plasticity in the hippocampus, namely favouring excitatory glutamatergic over inhib-
itory GABAergic pathway53. 
On the other hand, unpublished data from the host laboratory also reported a significant increase of 
meningeal IL-17-producing cells – mainly γδ T cells - in a transgenic mouse model of AD, associated 
with the onset of the disease. Importantly, local neutralization of IL-17 in 3xTg-AD mice prevented the 
development of short-term cognitive deficits and synaptic plasticity dysfunction (Brigas, H. et al., under 
review). These results underpin IL-17 as an early trigger of neuroinflammation and are aligned with 
previous reports showing a contribution of this cytokine to EAE94 and brain ischemia upon injury89,90. 
Accordingly, a dual role for IL-17 is proposed: pro-cognitive at steady state and anti-cognitive in the 
context of neurodegeneration. This implies a hypothetic optimal meningeal IL-17 threshold below which 
cognitive deficits would appear and above which pathogenic neuroinflammation would be triggered53. 
Therefore, a tight control of meningeal IL-17 homeostasis seems required to maintain brain integrity 
and cognitive functions. 
Building on these considerations, we proposed to investigate the underlying mechanisms that contribute 
to ensure meningeal IL-17-producing cells regulation. This control would optimize the levels of this 
cytokine necessary to guarantee optimal cognitive functions. Conversely, a dysregulation of these ho-
meostatic mechanisms would result in an escalation of meningeal IL-17 production leading to neuroin-
flammatory and neurodegenerative events with harmful consequences for brain physiology. 
Given their known important implications in the immune system and cognitive performance, we propose 
to explore a possible role for glucocorticoids, circadian rhythms and sleep on meningeal IL-17+ immune 
cell regulation. 
Thus, our main goals consist in: 
1) Analyzing the impact of glucocorticoids on IL-17+ immune cells upon in vitro and in vivo 
administration of the glucocorticoid receptor agonist dexamethasone. 
2) Characterizing the diurnal oscillation of meningeal IL-17+ immune cells in wild-type mice and 
in a neurodegenerative mouse model of Alzheimer’s Disease (3xTg-AD). 
3) Deciphering a potential influence of sleep for meningeal IL-17+ cells immune cells resorting to 
an anesthetic procedure. 
We believe that understanding the cellular and molecular mechanisms that regulate the homeostasis of 
the meningeal immune system will greatly advance our knowledge regarding the cascade of events that 





3. Material and Methods 
3.1 Mice 
C57BL/6J mice were purchased from Charles River Laboratories (Spain). 5- to 24-week-old (wo) males 
were used in all experiments. C57BL/6-129SvJ mice bearing three mutations (3xTg-AD) associated 
with familial AD (amyloid precursor protein [APPswe], presenilin-1 [PSEN1] and microtubule-
associated protein tau [MAPT])202 were purchased from the Jackson Laboratory and 30-wo females were 
used in the experiments. Transgenic mice overexpressing human alpha-synuclein (αSyn) under the  
Thy-1 promoter were generated on a mixed C57BL/6-DBA/2 background (Thy1-αSyn mice), as 
previously described203. Heterozygous female C57BL/6J-DBA/2 were bred with wild-type (WT) male 
B6D2F1 mice to generate homozygous male mice and their WT littermates analysed in this study at 24-
wo. Thy1-αSyn mice were kindly provided by Dr. Tiago Outeiro from Centro de Estudos de Doenças 
Crónicas (CEDOC). Mice were maintained at Instituto de Medicina Molecular (iMM) animal facility, 
housed under a 14h/10h light:dark cycle (light on for 14 hours from 7:00 a.m. to 9:00 p.m.) in specific 
pathogen–free conditions. For sleep studies, mice were housed in light-controlled cabinets under a 
reversed 24-hour dark:light cycle (light on for 12 hours from 8:00 p.m. to 8:00 a.m. as ZT0 to ZT12). 
Mice were maintained under these conditions for at least 3 weeks to habituate prior to experimentation. 
All mice were fed and watered ad libitum. The experiments were approved by the institutional Animal 
Welfare Body (ORBEA-iMM), submitted to the Direcção Geral de Alimentação e Veterinária (DGAV) 
for licensing and performed according to national and European regulations. 
3.2 Cell isolation 
Mice were euthanized with CO2 and transcardially perfused with cold 0.1 M phosphate-buffered saline 
(PBS), pH 7.4 (Corning Life Sciences). Meninges were dissected as described in the literature58. Briefly, 
surgical scissors were used to remove skull tops by making an incision along the parietal and squamosal 
bones. Dural meninges were carefully removed from the ventral and dorsal sides of the cranium and 
surfaces of the brain with forceps and collected in complete RPMI 1640 [+] L-Glutamine medium (10% 
fetal calf serum (FCS), 1% of sodium pyruvate, 1% of HEPES, 1% of MEM non-essential amino acid 
and 1% of penicillin and streptomycin) (ThermoFischer). Superficial cervical (scLNs) and/or peripheral 
lymph nodes, and the spleen were collected in complete RPMI medium. Cell suspensions were obtained 
by gently pressing meninges, scLNs and the spleen through a 70-μm nylon mesh cell strainer with a 
sterile plastic plunger. Cells suspensions were centrifuged at 1200 RPM for 8 min at 4°C. After 
discarding the supernatant, cell pellets were resuspended in complete RPMI medium. An additional Red 
Blood Cells lysis step was applied to spleen homogenates by resuspending and incubating the cells into 
a 1X solution of red blood cell (RBC) lysis buffer (Biolegend) for 2 min. All the organs were processed 
individually, except for meninges that were pooled from 2-4 mice in the indicated experiments. 
3.3 In vitro dexamethasone treatment 
Total γδ T cells (CD3+ TCRδ+), or CD27+ and CD27- γδ T cell subsets along with naïve CD4+ CD25- αβ 
T cells were isolated from a pool of peripheral (superficial cervical, axillary, brachial and inguinal) 
lymph nodes and spleens of 8-wo WT male C57BL/6J mice. Cell suspensions were prepared as de-
scribed above and negatively enriched in CD3+ cells by magnetic cell sorting (MACS) using anti-biotin 
microbeads (Myltenyi biotec) and biotinylated anti-CD11b and anti-CD19 antibodies (Biolegend). The 
enriched fraction was incubated 20 min with purified anti-CD16/CD32 mAbs (Fc block) (Ther-
moFisher) and stained for 20 min on ice with anti-CD3, anti-TCRδ, anti-CD27, anti-CD4 and anti-CD25 
antibodies and Live/Dead fixable dye (ThermoFisher) at 60x106 cells/ml in fluorescence-activated cell 
sorting (FACS) buffer (0.1M PBS supplemented with 3% FCS and 2mM EDTA). Subsequentially, the 




Sorted cells were stained with CellTrace™ Violet (CTV) Proliferation Kit (ThermoFisher) at a concen-
tration of 1 million cells/ml with 5µM CTV in 37ºC pre-warmed 0.1M PBS for 20 min at room temper-
ature. After washing, the cells were resuspended in complete RPMI (plus 0.1% of 2-Mercaptoethanol) 
(ThermoFisher) and poured in a 96 well U bottom plate previously coated with purified anti-CD3e an-
tibody (3 μg/ml, 145-2C11, Biolegend) by a 2h incubation at 37ºC. Murine IL-1β (10 ng/ml, PeproTech), 
murine IL-23 (10 ng/ml, R&D system) and murine IL-7 (40 ng/ml, PeproTech) (when applicable) were 
added, along with the specified concentrations of Dexamethasone (D4902, Sigma-Aldrich) or the vehi-
cle solution (ethanol absolute). Cells were incubated at 37°C in a 5% CO2 environment for 20h or 72h, 
collected and analysed by flow cytometry. 
3.4 In vivo dexamethasone treatment 
8-wo WT male C57BL/6J mice were injected intraperitoneally (ip) at ZT0,5 with dexamethasone 21-
phosphate disodium salt (200µg) (D1159, Sigma-Aldrich) or saline solution. Four hours later, the mice 
were sacrificed for ex-vivo analysis by flow cytometry.  
3.5 Anesthetic protocol 
8-wo WT male C57BL/6J mice on a reversed light:dark cycle were injected ip with a Ketamine (100 
mg/kg, Imalgene® - Merial) and Xylazine (10mg/kg, Seton 20mg/ml) solution (K/X), or saline solution 
at ZT12.5. One third of the initial dose of K/X or saline was administered at ZT13.5. K/X injected mice 
were maintained on a warm pad and sacrificed at ZT14 for ex vivo analysis by flow cytometry. 
3.6 Flow cytometry analysis 
Cells were stimulated in complete RPMI medium with PMA (Phorbol 12-Myristate 13-Acetate; 50 
ng/ml, P-1585, Sigma-Aldrich) and Ionomycin (1 μg/ml, I0634, Sigma-Aldrich) in presence of Brefeldin 
A (BFA) (10 μg/ml, B-6542, Sigma-Aldrich) for 3h-4h at 37°C 5% CO2. Cells were transferred into 96-
well V bottom plates and washed once in BFA-supplemented FACS buffer. For surface staining, cells 
were resuspended in BFA-supplemented FACS buffer containing purified anti-mouse CD16/CD32 
mAbs (ThermoFisher) for 15 min and 20 min with antibodies against the indicated cell surface markers 
(Table S1) and Live/Dead Fixable Viability dye (ThermoFisher) on ice at 60x106 cells/ml. For intracel-
lular staining, cells were fixed in Fixation/Permeabilization buffer (ThermoFisher) supplemented with 
BFA for 30 min on ice. Cells were washed with FACS buffer and stored overnight at 4ºC. The day after, 
cells were washed twice in Permeabilization buffer (Thermofisher) and incubated in permeabilization 
buffer with Rat IgG (Sigma-Aldrich) and purified anti-CD16/CD32 mAbs (ThermoFisher) for 15 min 
on ice. Intracellular staining mix, containing the appropriate antibodies (Table S1) was added and the 
cells were incubated for 30 min on ice. Cells were washed first in Permeabilization buffer and then in 
FACS buffer and resuspended in FACS buffer. In the indicated experiments, early and late apoptotic 
cells were stained by incubating unfixed cells at 10.106 cells/ml with anti-Annexin-V antibody and 7-
AAD in Annexin-V staining buffer (Biolegend) during 15 min at room temperature. FACS acquisition 
was performed on FACS Fortessa (BD Biosciences) cell analyser. The data was analysed using FlowJo 
software (BD biosciences) and the populations identified with the indicated gating strategy (Figure S3). 
3.7 Statistical analysis 
Statistical analysis and graphical representation of data were performed using GraphPad Prism 8.4.2 
software (GraphPad Software Inc., San Diego, CA, USA). Sample data are represented as mean ± stand-
ard deviation (SD) of n independent experiments. An unpaired two-tailed Mann-Whitney test and one-
way ANOVA with a Tukey’s multiple comparisons test were used when applicable. Results were con-
sidered significant when p < 0.05 or for lower significance thresholds (*p < 0,05; **p < 0,005; ***p < 





4.1 IL-17 is supplied by an heterogenous and tissue-specific pattern of immune cells 
IL-17 is a cytokine produced by multiple immune cell subsets throughout the body were exerts several 
immune regulatory functions. Interestingly, we found significant changes in the composition of IL-17+ 
immune cells between meninges and lymphoid organs (scLNs and spleen). In accordance with a 
previous report from the host laboratory53, we observed that meningeal IL-17 is mostly provided by γδ 
T cells in naïve WT mice (Figure 4.5B).  
Figure 4.5 – IL-17 is mostly provided by γδ T cells in meningeal spaces at steady state in opposition to lymphoid organs. 
Cell suspensions were prepared from meninges, superficial cervical lymph nodes (scLNs), and the spleen of 12-week-old wild-
type male C57BL6/J mice. Cells were analysed by flow cytometry for the expression of surface (CD45, CD19, CD3, TCRδ, 
CD4, and CD8) and intracellular (IL-17) markers. Live cells were gated using LiveDead Fixable Viability Dye. (A) 
Identification strategy for IL-17 producing immune cells among meningeal cells. (B) Pie charts indicating the proportion of 
each cell subsets to IL-17+ immune cell population in the indicated organs. Pie charts display the means values of data from 3 
independent experiments with n=6 for meningeal spaces (pooled from 2-3 mice), and n=15 mice for scLNs or spleen. 
By contrast, in the LNs IL-17 is mainly provided by other types of T cells, such as CD4+ (TH17), CD8+ 
T cells and CD3+ CD4- CD8- γδ- that can include NKT cells and MAIT cells; while in the spleen, it 
mostly comes from CD3- cells that can include ILC3s, NK cells, LTis and myeloid cells (Figure 4.5B). 
Hence, different tissues exhibit different immune populations responsible to produce IL-17 and an 
important contribution is provided by γδ T cells in the meningeal spaces. 
4.2 γδ17 T cells are enriched for the expression of receptors sensing environmental and 
endogenous cues 
Based on the dual role of IL-17 in the CNS, we searched for the underlying homeostatic mechanisms 
that could modulate the pattern of meningeal IL-17+ immune cells at steady state. Considering the 
preponderant contribution of γδ T cells to IL-17 production in the meningeal spaces53 (Figure 4.5B), 
we screened putative candidates that would enable γδ17 T cells to sense environmental and endogenous 
cues. 
Figure 4.6 – γẟ17 T cells are enriched for the expression of receptors sensing environmental and endogenous cues. IL-
17+, IFN-γ+ and IL-17-IFN-γ- (DN) γδ T cell subsets were sorted by FACS from peripheral LNs (superficial cervical, axillary, 







































































































































































































































































sequencing (RNA-seq). Histograms depict the expression of (A) receptors of neuromodulators - namely glucocorticoids 
(Nr3c1) and catecholamines (Adrb2, Adrenergic Receptor Beta 2) and (B) master clock genes Arntl (encoding for BMAL1) 
and Clock (encoding for CLOCK) on IL-17+, IFN-γ+ and DN γδ T cells. CPM: Counts Per Million. Data are from 3 independent 
experiments. One-way ANOVA with a Tukey’s multiple comparisons test. **** p<0.0001, *** p<0.001. [unpublished data 
from the host laboratory, by Tiago Amado and Anita Gomes]. 
The analysis of RNA sequencing (RNA-seq) data provided by the host laboratory (Tiago Amado, 
unpublished data), allowed us to observe a 2-4 fold increase in the expression of genes encoding for the 
glucocorticoid and β2ARs (Nr3c1 and Adrb2, respectively) by γδ17 T cells compared with the IFN-γ+ 
and double negative (DN) subsets, isolated from a pool of peripheral LNs of Il17a-GFP.IFN-γ-YFP 
double reporter mice (Figure 4.6A). These data suggest that peripheral γδ17 T cells, and possibly 
meningeal γδ17 T cells, are prone to respond to glucocorticoids and catecholamines (adrenalin and 
noradrenaline) produced in a stress-context107 or in a diurnal manner, driven by the circadian 
machinery111. 
Additionally, γδ17 T cells also displayed a higher expression of the master clock genes Artnl and Clock 
(Figure 4.6B), compared with IFN-γ+ and the DN subsets. Supporting these results, an independent in 
silico analysis of γδ17 T Vγ6+ cells transcriptional program has also pointed neuromodulators, hormones 
and circadian rhythm cues as new biological pathways involved in the maturation process of this cell 
subset204. Interestingly, the majority of meningeal γδ17 T cells are Vγ6+ cells53. 
Altogether, we postulated that stress-related neuromodulators and/or internal circadian oscillators could 
shape the meningeal homeostasis of IL-17+ immune cells. 
4.3 Analysis of the impact of stress on IL-17-producing immune cells 
4.3.1 In vitro glucocorticoid agonist dexamethasone promotes γδ17 T cell 
preferential survival and proliferation 
Glucocorticoid release is a fundamental part of the stress response with powerful 
neuroimmunomodulatory functions205. To investigate a possible role of stress on the production of IL-
17, we first investigated the impact of glucocorticoids in γδ T cells using an in vitro experimental 
approach. Due to the limited number of meningeal γδ T cells, we sorted total γδ T cells from LNs and 
spleen and cultured them for 72h with different concentrations of the high affinity synthetic 
glucocorticoid, dexamethasone. 
We observed a drop in the total number of γδ T cells that received the highest concentration of 
dexamethasone (10-6M), revealing a dose-dependent immunosuppressive effect mediated by GRs 
activation (Figure 4.7A). In addition, a ten-fold increase and two-fold decrease among the remaining 
live γδ T cells was observed for the proportions of IL-17+ (Figure 4.7B) and IFN-γ+ cells (Figure S4), 
respectively, although their individual cytokine production – IL17 and IFN-γ geomean fluorescence 
intensities, (gMFI) – were unaffected (Figure 4.7B and Figure S4). In this condition, we postulate that 
the substantial enrichment of IL-17+ γδ T cells would be the result from a dexamethasone-induced 
apoptosis of other γδ T cells. Nonetheless, when γδ T cells were incubated with a lower concentration 
of dexamethasone (10-8M), we observed a 2-fold increase in IL-17+ cells (Figure 4.7B), while the 
percentage of IFN-γ producers was similar (Figure S4), as well as the absolute cell numbers (Figure 
4.7A). Therefore, the enrichment observed in γδ17 T cells after the dexamethasone treatment still takes 
place in the absence of apoptosis observed at high concentrations. 
This first set of data suggests a differential effect of the dexamethasone treatment on γδ T cell subsets, 
promoting or depleting them, in a dose-dependent manner. 
To confirm this differential effect, we sorted γδ T cells based on their expression of CD27, allowing to 
obtain populations enriched in IL-17 producers (γδ27- subset) and IFN-γ producers (γδ27+ subset)206. 
These cells were cultured separately in the presence of 10-8 M of dexamethasone (optimal concentration, 
as defined in Figure 4.7B) for 20h to consider a possible early effect mediated by GRs stimulation. As 




glucocorticoid signalling142. To assess the effect of dexamethasone on survival and proliferation, we 
resorted to a Live-Dead staining and Cell Trace Violet (CTV) dilution method, respectively. 
Figure 4.7 – In vitro dexamethasone treatment of γδ T cells favours the IL-17+ cells survival and proliferation. Total γδ 
T cells were sorted by FACS from the peripheral LNs (superficial cervical, axillary, brachial and inguinal LN) and the spleen 
of 8-week-old wild-type male C57BL/6J mice. Cells were cultured in presence of anti-CD3e antibody (3 μg/ml, plate bound), 
IL-1β (10 ng/ml), IL-23 (10 ng/ml) and IL-7 (40 ng/ml); and treated with a dexamethasone (DEX) or the vehicle solution. (A) 
Total cells were counted after 72 hours of culture with different concentrations of dexamethasone (10-10 M, 10-8 M and 10-6 M), 
and analysed by flow cytometry for the expression of surface (CD3, TCRδ) and intracellular (IL-17) markers. Live cells were 
gated using LiveDead Fixable Viability Dye. (B) Representative dot plots displaying the IL-17+ cells among 10000 
dexamethasone or vehicle-treated live γδ T cells (left), their quantification (middle), and their geomean fluorescence intensity 
(gMFI) (right). CD27+ or CD27- γδ T cells, and naïve CD4+ T cells were treated with dexamethasone (10-8 M) or vehicle 
solution, in the culture conditions described above (without IL-7) for 20 hours. Total cells were collected and analysed by flow 
cytometry for their (C) survival (LiveDead dye), (D) proliferation (Cell Trace Violet dye dilution) and (E) their surface 
expression of the IL-7 receptor (IL-7R). (D, E) Empty dark histogram: dexamethasone-treated cells, Grey-filled histogram: 
vehicle-treated cells. Data extracted from three independent experiments. Mean ± SD. 
Our results confirmed a cell subset-specific effect of dexamethasone with the induction of massive 
apoptosis of treated γδ27+ cells and naïve CD4+ T cells, while γδ27- T cell survival was unaffected 
(Figure 4.7C). Additionally, γδ27- T cells exhibited a higher proliferation only 20 hours after the 
dexamethasone treatment (Figure 4.7D).  
Since glucocorticoids can modulate T cell homeostasis through a direct induction of IL-7R, promoting 
the survival, proliferation and differentiation of T cells142, we analysed its surface expression as a 
functional read-out of GR activation207. We observed a 2-3 fold overexpression of the IL-7R in response 
to dexamethasone stimulation, particularly in the γδ T cell subsets (Figure 4.7E), while naive CD4+ T 
cells significantly overexpressed IL-7R for higher concentrations of dexamethasone (10-6M) (data not 
shown). These results validated the GR activation of IL-17+ and IFN-γ+ enriched cell subsets and suggest 
a higher affinity or more pronounced response of γδ T cells to dexamethasone, compared with αβ CD4+ 
T cells.  
Therefore, glucocorticoids can modulate the effector functions, proliferation and survival of peripheral 











































































































































After 72 hours of culture 





4.3.2 In vivo dexamethasone administration does not alter meningeal IL-17+ 
immune cells homeostasis 
To test a possible in vivo glucocorticoid role in meningeal IL-17+ cell homeostasis, we injected WT mice 
with dexamethasone or vehicle solutions in the beginning of their resting phase (lowest glucocorticoid 
level period) and analysed meninges, scLN and spleen after four hours by flow cytometry (Figure 4.8A). 
Figure 4.8 – In vivo dexamethasone administration does not alter meningeal IL-17+ immune cells homeostasis. 
(A) Experimental procedure: 7-wo WT male C57BL6/J mice received an ip injection of dexamethasone (DEX, 200 μg) or 
vehicle saline solution at ZT0,5 (normal light-dark cycle), and were sacrificed 4 hours later. Cell suspensions were prepared 
from the indicated organs. Cells were analysed by flow cytometry for the expression of surface (CD45, CD19, CD3, TCRδ, 
CD4 and CD8) and intracellular (IL-17) markers. Live cells were gated using LiveDead Fixable Viability Dye. Absolute 
numbers of live CD45+ cells from the (B) meningeal, (F) scLNs and (H) spleen cell suspensions were calculated. (C) 
Smoothened dot plots depicting IL-17+ cells among 900 live CD45+ cells isolated from meninges of dexamethasone or vehicle-












































































































































































































































































































































































































































































treated animals (left), their quantification (middle), and their geomean fluorescence intensity (gMFI) (right). The same 
quantifications were made for scLNs in (G) and spleen cell suspensions (I). (D, J, L) Percentages of IL-17+ cells among CD3+γδ 
T cell, CD3+CD4+ T cell, CD3+CD8+ T cell, CD3+CD4- CD8- T cell and non-T cell subsets; (E, K, M) and percentages of these 
cell subsets among total live CD45+ cells. Data are from 1 independent experiment, n=3 mice per group. Mean ± SD. 
We performed an extended analysis of cell functions (IL-17 and IFN-γ production), proliferation, 
survival and migration properties of a large panel of individual lymphocyte subsets. In these 
experimental settings, meninges did not display significant changes in the percentage of IL-17 among 
leukocytes (Figure 4.8C) or the different subsets (Figure 4.8D) after the dexamethasone treatment and 
only an increase in CD3- cells among total leukocytes could be perceived (Figure 4.8E).  
However, a differential re-shaping of peripheral immune cells was observed in dexamethasone-treated 
animals. A decrease in the number of leukocytes, IL-17+ cells and IL-17 expression could be observed 
in the spleen (Figure 4.8H, I), while in the scLNs we observed a slight increase of IL-17+ cells (Figure 
4.8G). Interestingly, the major difference in the percentage of IL-17 was found among γδ T cells from 
both organs (Figure 4.8J, L). 
Similarly, dexamethasone did not impact the expression of IFN-γ in the meninges (Figure S5A), while 
a drop could be observed in the peripheral lymphoid tissues, particularly in the spleen (Figure S5B, C). 
Although not significant, the dexamethasone treatment also induced an overall reduction of the different 
IL-17 immune cell producers in the spleen of dexamethasone-treated animals (Figure 4.8M), suggesting 
that the limitation of splenic IL-17 production might be a consequence of a substantial cell apoptosis 
driven by the treatment. In the scLNs we only observed a drop in CD4+ and CD8+ T cells (Figure 4.8K, 
M), two subsets known to be regulated by glucocorticoids140,142, suggesting that the IL-17+ cell increase 
resulted from an enrichment in γδ17 T cells (Figure 4.8J). However, a recirculation of IL-17+ cells 
between both lymphoid organs cannot be excluded. 
These data indicate that early dexamethasone treatment has a dual role in the homeostasis of IL-17+ cells 
in a lymphoid tissue-specific manner but does not affect meninges. 
4.3.3 In vivo dexamethasone administration differentially affects IL-17 immune cell 
producer homeostasis in the scLNs 
To further explore the underlying mechanisms of in vivo IL-17+ cell modulation in the scLNs by the 
dexamethasone treatment, we performed an annexin V binding buffer and 7-AAD staining to identify 
early versus late (apoptotic) cells, a ki-67 staining to confirm the proliferative status and a RORγt 
staining to evaluate the differentiation of different cell subsets. 
Due to incompatibility of intracellular cytokine staining with annexin V kit, we used the differential 
expression of the surface CD44 and CD45RB markers to segregate γδ T cells into subsets with IL-17A- 
or IFN-γ-secreting potential or DN among CD24- cells, as previously described208. According to what 
we previously described with the intracellular staining, we could observe an increase in the percentage 
of IL-17+ committed γδ T cell subset ([d] CD44+ CD45RB-) and a concomitant decrease in IFN-γ+ com-
mitted γδ T cell subsets ([b] CD44- CD45RB+ and [c] CD44+ CD45RB+), while no differences were 
observed in the DN subset ([a] CD44- CD45RB-) (Figure 4.9A). 
As expected, we observed a 2-fold increase in the amounts of early and late apoptotic cells among IFN-
γ committed and the DN subsets in sharp contrast with the IL-17 committed subset, whose apoptotic 
cell populations were unaffected by the dexamethasone treatment (Figure 4.9C). Besides γδ T cells, 
CD4+ and CD8+ T cells were the subsets more affected by the dexamethasone treatment (Figure 4.9D). 
Of note, an overexpression of IL-7R was observed in the populations more responsive to the dexame-
thasone treatment, i. e., γδ T cells, CD4+ and CD8+ T cells (Figure S6). 
On the other hand, we detected an enrichment in Ki67+ cells among the γδ T cells of dexamethasone 
treated mice (Figure 4.9E). Interestingly, these proliferative cells were enriched in RORγt-expressing 




These results validated our in vitro data by reporting a cell-differential pro-apoptotic or proliferative 
program downstream of the GR activation that favors the γδ17 T cell population.  
Figure 4.9 – In vivo dexamethasone administration differentially affects the γδ T cell homeostasis in the scLNs. 7-wo 
WT male C57BL6/J mice received an ip injection of dexamethasone (DEX, 200 μg) or vehicle saline solution at ZT0,5 (normal 
light-dark cycle), and were sacrificed 4 hours later. Cell suspensions were prepared from superficial cervical lymph nodes 
(scLNs) and were analysed by flow cytometry for the expression of surface (CD3, TCRδ, CD4, CD8, CD24, CD45RB, CD44, 
Annexin-V) markers and 7-AAD dye for the live/dead cell discrimination. (A) Identification (left) and quantification (right) of 
γδ T cell subsets as previously described208. (B) Representative contour plots of early (Annexin-V+ 7-AAD+) and late (Annexin-
V- 7-AAD+) apoptotic cells among indicated γδ T cell subsets isolated from the scLNs of dexamethasone or vehicle-treated 
animals. (C) Quantification of early and apoptotic cells among γδ T cell subsets (D) and other identified immune cell subsets. 
Cells were in parallel analysed for their expression of intracellular (Ki67, RORγt) markers. Live cells were gated using Live-
Dead Fixable Viability Dye. (E) Representative contour plots of proliferative Ki67+ cells among total γδ T cells in dexame-
thasone or vehicle-treated animals (left), and their quantification. (F) Representative contour plots of proliferative RORγt+ cells 
among Ki67+ γδ T cells in dexamethasone or vehicle-treated animals (left), and their quantification. Data are from one inde-
pendent experiment, n=2-3 mice per group. Mean ± SD. 
4.4 Putative circadian control of meningeal immune cells in pathophysiological conditions 
4.4.1 Meningeal IL-17+ immune cells exhibit a diurnal oscillatory pattern in the 
meninges of wild type mice 
Considering the expression of circadian clock genes in γδ17 T cells (Figure 4.6B), we questioned a 
possible time-of-the-day regulation of IL-17+ immune cells in the meninges that could optimize the IL-
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Figure 4.10 – The proportion of IL-17+ immune cells exhibit a diurnal oscillatory pattern in the meninges of wild-type 
mice. (A) Experimental procedure: 17-wo WT male C57BL/6J mice were sacrificed at ZT7, ZT15, and ZT23 (normal light:dark 
cycle) within the same day. Cell suspensions were prepared from the indicated organs. Cells were analysed by flow cytometry 
for the expression of surface (CD45, CD19, CD3, TCRδ, CD4 and CD8) and intracellular (IL-17) markers. Live cells were 
gated using LiveDead Fixable Viability Dye. Absolute numbers of live CD45+ cells from (B) meningeal, (F) scLNs and (H) 
spleen cell suspensions were calculated. (C) Smoothened dot plots depicting IL-17+ cells among 2000 live CD45+ cells isolated 
from meninges at the indicated ZT (left), their quantification (middle), and their geomean fluorescence intensity (gMFI) (right). 
The same quantifications were made for (G) scLNs and (I) spleen cell suspensions. (D, J, L) Percentages of IL-17+ cells among 
CD3+γδ T cell, CD3+CD4+ T cell, CD3+CD8+ T cell, CD3+CD4- CD8- T cell and non-T cell subsets; and (E, K, M) percentages 
of these cell subsets among total live CD45+ cells. Data are from 3 independent experiments, with n=3 individual measures per 
timepoint for meninges (obtained by pooling meningeal spaces of 3-4 mice), and n=3 mice per timepoint for the scLNs or 
spleen. Mean ± SD. A non-linear Cosinor regression was applied in (B, F, G, J, K) for the diurnal oscillation modelling. Mann-
Whitney test, * P<0,05. 














































































































































































































































































































































































































































































































For this, we analysed the meninges, scLN and spleen of WT mice kept under a normal light:dark cycle 
by flow cytometry at 3 timepoints: ZT7 (2 p.m.), ZT15 (10 p.m.) and ZT23 (6 a.m.) (Figure 4.10A). 
First, we found an increase in the absolute number of meningeal leukocytes during the night (Figure 
4.10B). Interestingly, the percentage of IL-17+ cells exhibited a diurnal oscillatory pattern by fluctuating 
±50% in the meninges with a bathyphase (the lower part of the circadian pattern) during the day (ZT7) 
and an acrophase (the highest part of the circadian pattern) during the night (ZT19), while IL-17 gMFI 
remained stable (Figure 4.10C). Dissecting the individual subset contribution to IL-17 oscillation, we 
observed an overall increase in the percentage of IL-17+ cells among the different considered subsets 
(exception for CD8+ T cells), particularly in γδ T cells and CD3- cells (Figure 4.10D). Additionally, we 
observed an increase in CD3- cells and CD4+ T cells at ZT23 (Figure 4.10E). 
To then test a possible cell recirculation that could contribute to the diurnal oscillation of IL-17+ cells in 
the meningeal spaces, we analysed the scLNs that were already described to participate in the continuous 
drainage of immune cells from the meningeal spaces38, as well as the spleen. Consistent with previous 
findings, we observed an oscillation in the number of leukocytes that peaked during the night in the 
LNs133,209 (Figure 4.10F) and a decrease in the spleen (Figure 4.10H). Interestingly, compared to the 
meningeal spaces, no fluctuation seems to occur in the percentage and gMFI of IL-17 from scLN 
(Figure 4.10G) or spleen (Figure 4.10I), suggesting that the meningeal oscillation is not the result of a 
recirculation through scLNs and spleen. Noteworthy, we found that meningeal IFN-γ+ cells also exhibit 
a diurnal oscillation in the meninges with an acrophase at ZT23 (Figure S7A), while no differences 
were found in the peripheral lymphoid tissues over our time course analysis (Figure S7B, C). 
Altogether, these data suggest a circadian control of immune cell functions in the meninges, featuring 
an increase of IL-17+ and IFN-γ+ cells during the active phase of the animal. 
4.4.2 Meningeal IL-17+ immune cells do not exhibit a diurnal oscillatory pattern in 
3xTg-AD mouse model 
Considering that neurodegenerative diseases are generally associated with circadian disturbances161 and 
the meningeal IL-17 accumulation at AD onset (Brigas, H. et al., under review), we next hypothesized 
that early impairments in the circadian rhythms could lead to a dysregulation of IL-17-producing cell 
homeostasis, in the context of AD. To follow up on this hypothesis, we used the triple-transgenic mouse 
model of AD (3xTg-AD), a progressive model of the disease, to characterize a possible dysregulation 
of the diurnal oscillation of IL-17+ cells in the meningeal spaces. These mice co-express three mutations 
associated with familial AD202 (Figure 4.11A) and, in females, the onset of disease occurs at 5-6-months 
old (mo) with mild cognitive impairments, while the neuropathology and severe memory deficits are 
established at 8 mo202,210–212. Here, we analysed 7.5 mo 3xTg-AD females and their age- and sex-matched 
control at 2 different timepoints: ZT7 (2 p.m.) and ZT19 (2 a.m.) (Figure 4.11B), that would correspond 
to meningeal IL-17+ cells bathyphase and acrophase, respectively, according to our previous results. 
As previously described (Brigas, H. et al., under review), we observed a 40-50% increase in IL-17+ cells 
in meninges (Figure 4.11C), scLNs (Figure 4.11I) and spleen (Figure 4.11K) of AD transgenic mice 
compared with the WT controls. Unexpectedly, in the meningeal spaces, we found no differences in the 
number of leukocytes between the two timepoints (Figure 4.11B), nor an oscillation of IL-17+ cells in 
WT and AD mice (Figure 4.11C). Contrary to what was previously observed (Figure 4.10), a decrease 
in the IL-17 expression (Figure 4.11C) and IL-17+ cell percentage specifically among γδ T cells was 
found during the night in WT and AD mice (Figure 4.11D, F). In the peripheral lymphoid tissues, and 
again contrary to was previously observed (Figure 4.10), we did not find an increase in the number of 
leukocytes in the scLNs (Figure 4.11H) or a decrease in the spleen (Figure 4.11J) during the night, 
both in WT and AD mice. No significant changes in the percentage of IL-17+ cells in the scLNs and 




Of note, meningeal IFN-γ+ cells also exhibited no diurnal oscillation, while a decrease in IFN-γ+ expres-
sion in meninges was observed during the night in both WT and AD mice (Figure S8A). The same 
results were found in the spleen of WT and AD mice during the night (Figure S8C), while both param-
eters remained stable in the scLNs (Figure S8B). 
The absence of differences and inconsistency compared with the previously results obtained impaired 
us to draw any particular conclusions at this point. 
Figure 4.11 – The proportion of IL-17+ immune cells in the meninges of a 3xTg-AD mice do not display a diurnal 
oscillatory pattern. (A) Experimental procedure: 7-month-old WT and 3xTg-AD female C57BL/6J-129SvJ mice were 
sacrificed at ZT7 and ZT19 (normal light:dark cycle). Cell suspensions were prepared from the indicated organs. Cells were 
analysed by flow cytometry for the expression of surface (CD45, CD19, CD3, TCRδ, CD4 and CD8) and intracellular (IL-17) 
markers. Live cells were gated using LiveDead Fixable Viability Dye. Absolute numbers of live CD45+ cells from (B) 
meningeal, (H) scLNs and (J) spleen cell suspensions were calculated. (C) Smoothened dot plots depicting IL-17+ cells among 
500 live CD45+ cells isolated from meninges at the indicated ZT (left), their quantification (middle), and their geomean 
fluorescence intensity (gMFI) (right). The same quantifications were made for the (I) scLNs and (K) spleen cell suspensions. 
Percentages of IL-17+ cells among CD3+γδ T cell, CD3+CD4+ T cell, CD3+CD8+ T cell, CD3+CD4- CD8- T cell and non-T cell 
subsets in meninges of (D) WT and (F) 3xTg-AD mice. Percentages of indicated cell subsets among meningeal live CD45+ 
cells in (E) WT and (G) 3xTg-AD mice. Data are from 1 independent experiment, with n=4-5 mice per group and per timepoint. 
Mean ± SD. Mann-Whitney test, * P<0,05. 
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4.5 Analysis of the impact of sleep on IL-17-producing immune cells 
4.5.1 Anesthetized mice exhibit a decrease in meningeal IL-17+ immune cells 
Besides circadian disturbances, AD patients also suffer sleep perturbations213. Thus, given our 
inconclusive observations gathered from Figure 4.11, we next hypothesized that sleep could also 
regulate the homeostasis of meninges IL-17 immune cell producers. 
Figure 4.12 – Meningeal IL-17+ immune cells proportion is reduced after a ketamine/xylazine-induced anesthesia. 
(A) Experimental procedure: 9-wo WT male C57BL6/J mice received an ip injection of ketamine (100 mg/kg)/ xylazine (10 
mg/kg) (K/X) or vehicle saline solution at ZT12,5 (8.30 a.m.) (inverted light-dark cycle). After one hour, the anesthesia was 
prolonged by the injection of 1/3 of the initially administered dose of K/X. Mice were analysed at ZT14 (10 a.m.), and cell 
suspensions were prepared from the indicated organs. Cells were analysed by flow cytometry for the expression of surface 
(CD45, CD19, CD3, TCRδ, CD4 and CD8) and intracellular (IL-17) markers. Live cells were gated using LiveDead Fixable 
Viability Dye. Absolute numbers of live CD45+ cells from (B) meningeal, (F) scLNs and (H) spleen cell suspensions were 


























































































































































































































































































































































































































































































calculated. (C) Smoothened dot plots depicting IL-17+ cells among 1000 live CD45+ cells isolated from meninges of the awake 
(vehicle-treated) or anesthetized (K/X-treated) animals (left), their quantification (middle), and their geomean fluorescence 
intensity (gMFI) (right). The same quantifications were made for the scLNs in (G) and spleen cell suspensions (I). (D, J, L) 
Percentages of IL-17+ cells among CD3+γδ T cell, CD3+CD4+ T cell, CD3+CD8+ T cell, CD3+CD4- CD8- T cell and non-T cell 
subsets; (E, K, M) and percentages of these cell subsets among total live CD45+ cells. Data are from 1 independent experiment, 
n=2-3 per group. Mean ± SD. 
To test this hypothesis, we injected WT mice with an anesthetic solution of Ketamine/Xylazine in the 
beginning of the dark phase that reproduces the main features of sleep185. In these conditions, the control 
mice were at their awake phase (since mice are nocturnal) and were injected with a saline solution 
(vehicle). The mice were sacrificed one hour and a half later (Figure 4.12A). 
Unexpectedly, the number of meningeal leukocytes was strongly increased after only one and a half 
hour of anesthesia, revealing a major influence of the sleep state in meningeal immunity (Figure 4.12B). 
Interestingly, a 2-fold reduction in the percentage of IL-17+ cells and IL-17 expression, compared with 
vehicle-injected mice was observed (Figure 4.12C). Accordingly, a ±30% decrease in the overall 
percentages of γδ T cells, CD4- CD8- and CD3- among total leukocytes was observed in anesthetized 
mice (Figure 4.12E), which might account for the observed reduction in IL-17+ cells, given their 
important contributing for IL-17 production (Figure 4.12D). Although no changes in the number of 
leukocytes were observed in the scLNs (Figure 4.12F), an increase was observed in the spleen (Figure 
4.12H). Of note, no other changes were observed regarding the percentage of IL-17+ cells, IL-17 
expression, or its cellular contributors in the scLNs (Figure 4.12G, J) and spleen (Figure 4.12I, L), 
between vehicle and anesthetized mice. As observed with IL-17+ cells, a decrease in IFN-γ+ cells took 
place specifically in the meningeal spaces of anesthetized mice (Figure S9A), with no significant 
changes in the periphery (Figure S9B, C). 
These findings suggest that sleep is a modulator of the cellularity and the cytokine content in the 
meningeal spaces and might represent another important mechanism contributing to brain homeostasis. 
5. Discussion 
IL-17 is a cytokine with critical pleiotropic implications in pathophysiology, namely in the meninges, 
being pro-cognitive at steady state53 and anti-cognitive in the context of neurodegeneration (Brigas, H. 
et al., under review). Based on this intriguing background, we decided to drive an exploratory study to 
unravel possible homeostatic mechanisms implicated in the regulation of meningeal IL-17. 
To do so, we screened putative candidates from the transcriptomic landscape of γδ17 T cells (Tiago 
Amado, unpublished data) that highlighted hormones and neuromodulators, such as glucocorticoids and 
catecholamines, and circadian rhythm cues, results further supported by data from the literature204. Thus, 
we postulate that these biological processes would be crucial for γδ17 T cell homeostasis. This data 
should be validated resorting to reverse transcription polymerase chain reaction (RT-PCR) techniques. 
Due to technical limitations, it was not possible to sort enough γδ17 T cells from the meninges to run 
functional assays. This notwithstanding, and as a proof of concept, we could isolate γδ17 T cells from 
LNs and spleen to perform in vitro cell cultures and analyze the impact of glucocorticoids on these cells. 
We observed that glucocorticoid stimulation increased γδ17 T cells in a dose-dependent manner and 
decreased IFN-γ+ cells at high concentrations, specifically by promoting γδ27- T cells survival, 
proliferation and the overexpression of IL-7R. Interestingly, IL-7 signalling is particularly important to 
the activation of γδ cells competent to produce IL-17 through a STAT3 mediated process214. However, 
considering that γδ27- increased proliferation occurred in culture settings were no IL-7 was present, a 
glucocorticoid-mediated expansion of γδ17 T cells by an IL-7R-independent mechanism also takes 
place. Additionally, IL-7 signaling does not account for the enhanced survival of γδ17 T cells, as 
previously demonstrated214. Therefore, the glucocorticoid regulation of γδ17 T cells is not exclusively 
dependent of IL-7R overexpression and the molecular response to GR stimulation still needs further 




production might also result from an increase in IFN-γ+ cell apoptosis or a potential effect on γδ T cell 
differentiation. Nevertheless, in an in vitro culture setting, γδ17 T cells are highly responsive to 
glucocorticoid stimulation, as firstly predicted by the RNA-seq data. 
Alongside the fundamental role of glucocorticoids in stress responses, a daily peak of glucocorticoids is 
observed in the beginning the active phase with important immunomodulatory functions142. Considering 
our in vitro data, this daily glucocorticoid peak could induce a response of meningeal IL-17 immune 
cell producers to prepare the organism for daily tasks requiring short-term working memory. On the 
other hand, acute stress response is associated with enhanced synaptic plasticity and facilitates spatial 
learning149, two cognitive properties known to be modulated by IL-17+ cells in the meningeal spaces53.  
An association between stress and IL-17 cytokine response signature was already proposed by a 
transcriptomic analysis of cortices from stressed animals59. To observe if glucocorticoids could 
influence IL-17 immune cell producer homeostasis in vivo, we performed a flow cytometry analysis of 
meninges, LNs and spleen from mice injected with dexamethasone 4h before. In these experimental 
settings, dexamethasone stimulation had no impact on meningeal IL-17+ nor IFN-γ+ cells, while 
impacting the peripheral IL-17+ cell pool. Importantly, the direct induction of IL-7R on T cells by 
glucocorticoids here observed is responsible for the diurnal regulation of CXCR4 expression, a receptor 
critically involved in the redistribution of immune cells between LNs, spleen and blood142. Therefore, a 
possible effect of glucocorticoids on IL-17 immune cell producer recirculation between the scLNs and 
spleen might underly the differences observed in IL-17+ cells. However, given our in vitro results and 
in vivo extended analysis in scLNs, a glucocorticoid-mediated increase in IL-17+ cells might also result 
from an increased expansion, survival or differentiation of γδ17 T cells. Simultaneously, a massive 
apoptosis of splenic cells could have resulted in the observed IL-17+ cells drop. 
The unexpected absence of an effect of dexamethasone on the meningeal subsets might have several 
explanations. On one hand, 4h might not have been sufficient to observe an effect of glucocorticoids in 
the meningeal spaces. It was previously shown that a peak of IL-17 is observed 4h after acute stress 
induction, which induces a corticosteroid increase response within 15 minutes215. However, these re-
sponses were observed in the blood, meaning that the tissular responses might be delayed. Also, since 
the injection was intraperitoneal, the availability of the drug might be higher for the spleen and, in less 
extend, for the LNs, than for meninges. Additionally, IL-17 production in lymphoid tissues is mostly 
accounted by the Vγ4+ γδ T cell subset216, while in the meninges IL-17 is provided by Vγ6+ γδ T cells. 
Therefore, and since our RNA-seq analysis was performed in γδ T cells isolated from peripheral LNs, 
this subset might be more prone to respond to glucocorticoids. To address these issues, further studies 
should include a later monitoring of meningeal IL-17+ cells after dexamethasone injection and intracer-
ebroventricular injections of dexamethasone to question a possible bioavailability issue. Another im-
portant pharmacological approach would be the injection of mifepristone, an antagonist of GRs, to eval-
uate the impact of the endogenous glucocorticoid secretion. Finally, to assess a glucocorticoid specific 
effect on IL-17 immune cell producers and its implications for brain cognitive functions, mice with a 
conditional deletion of Nr3c1-encoded GRs on RORγt expressing cells should be used. Additionally, 
acute stress induction studies resorting to mice restrainment, social isolation, cage switch or retro-orbital 
bleeding, amongst others215 could help to clarify a possible effect of endogenous stress on the homeo-
stasis of IL-17+ cells in the meninges. 
Another important part of the stress response that was not explored in this study is the SNS regulation 
of immune responses. The high expression of Adrb2 by γδ17 T cells compared to their IFN-γ counterpart 
and DN cells (Tiago Amado, unpublished data), suggests another possible homeostatic mechanism ex-
erting a modulation of meningeal IL-17+ cells. Recent studies have shown that NK cells functional prop-
erties can be modulated by adrenaline and noradrenaline binding to β2ARs expressed by these cells. 
Interestingly, while in early innate responses adrenergic signals negatively regulated IFN-γ responses 




adrenergic signalling was necessary to elicit NK adaptive responses in a cell-intrinsic manner and fun-
damental to control MCMV replication218. This differential control of immune responses through non-
exclusive mechanisms emphasizes the complexity of stress responses on immune cell functions.  
To further explore other possible mechanisms regulating the homeostasis of meningeal IL-17+ cells, we 
investigated a potential diurnal control of this subset. We observed that IL-17+ cells in the meningeal 
spaces from WT mice subjected to a normal light:dark cycle exhibited a diurnal oscillation that peaked 
during the active phase of the animal. Interestingly, considering the important role of IL-17 in short-
term memory spatial working memory53, a higher availability of the cytokine in the meningeal spaces 
during the active phase of the animal could be considered an evolutionary advantage, preparing the 
organism to perform cognitive tasks. Accordingly, in humans, a cognitive circadian control is observed 
with cognitively complex tasks requiring short-term memory peaking in the middle of the active 
phase173. 
Interestingly, IFN-γ+ cells also exhibited a diurnal oscillation exclusively in the meninges that peaked 
during the active phase. This cytokine exerts a direct activation of the inhibitory prefrontal cortex (PFC) 
neurons supporting appropriate social behaviour, that is impaired in the absence of T cells or T cell-
derived IFN-γ59. Therefore, a circadian control of IFN-γ+ cells in the meningeal spaces would also be 
evolutionary advantageous to the organism to promote social interaction during their active phase. 
Importantly, circadian cues have shown to control several aspects of IL-17 cell producers physiology in 
the gut, namely their trafficking142, homeostasis in tissue and functions168,169. Mechanistically, a 
circadian regulation of TH17 differentiation was shown to be exerted by NFIL3 direct repression of Rorγt 
transcription. REV-ERBα, whose expression is regulated by BMAL1/CLOCK, can directly repress Nfil3 
transcription, thereby promoting Rorγt transcription and increasing TH17 frequencies170. We observed 
that meningeal IL-17+ immune cells increase their expression of IL-17 during the night, suggesting that 
a diurnal control of Rorγt transcription might led to an in situ differentiation also in the meninges. 
Accordingly, no changes in IL-17+ cells were observed in the scLNs or the spleen, indicating that this 
increase may not be due to a recirculation of IL-17-immune cell producers over 24h.  
Considering the hormonal and neuroendocrine circadian control, the peak of glucocorticoids and 
catecholamines in the beginning of the awake phase might contribute for the diurnal oscillation here 
observed. From what was explored in this study, glucocorticoids can modulate two important IL-17 
producers, γδ17 T cells and CD4+ T cells. Even though we could not observe an effect in vivo, an 
endogenous glucocorticoid peak might influence the meningeal spaces more than 4h later and contribute 
to the IL-17+ cell increase observed during the active phase of the animal, by affecting their proliferation, 
survival and differentiation. The injection of GRs antagonists would help to tackle this question. 
Additionally, adrenergic cues are also associated with a rhythmic recruitment of immune cells to tissues 
that is achieved through a circadian expression of endothelial cell adhesion molecules and chemokines 
on non-hematopoietic cells and a differential responsiveness of chemoattractant receptors132. Important 
biological consequences of this immune control include overall survival in models of septic shock, sickle 
cell vaso-occlusion and bone marrow transplantation209, as well as enhanced humoral immune responses 
during the active phase133. Although we found no evidences that IL-17+ cell oscillation were the result 
of a recirculation, these cues are also involved in the modulation of the functional properties of NK 
cells217,218, ILC2s219, CD4+ T cells220, and other innate and adaptive immune cell responses. 
Consequently, a possible adrenergic control of IL-17 immune cell producers must be considered in 
future studies. For this, the use of pharmacological agonists of β2ARs, such as clenbuterol, chemical 
denervation using 6-hydroxydopamine (6-OHDA) or adrb2-/- mice should be considered. 
Of note, the data on diurnal oscillations result from only one independent experiment per timepoint, thus 
the observed pattern would need to be strengthened with more samples. Also, for a more accurate control 
of diurnal oscillations, a 12h:12h light:dark system should be used221, instead of the 10h:14h currently 




PCR and perform IL-17 quantification studies in the meninges by enzyme-linked immunosorbent assay 
(ELISA) at different timepoints, since the methodology used in this study requires 3h-4h of cytokine 
stimulation in culture ex vivo during which cells continue their progression through the circadian cycle 
and might reach points in the cycle were the differences in cytokine expression are more attenuated169. 
Furthermore, it is important to mention that the involvement for the circadian rhythms can only be 
established by direct manipulation of intrinsic clock signals such as an ablation of the master circadian 
activator Arntl222, extrinsic clock signals such as SCN ablation223 or light:dark cues manipulation224. 
Such manipulations, specifically a conditional deletion of Arntl on Rorγt expressing cells, would allow 
us to prove a circadian control and further assess possible behaviour deficits induced by a putative 
circadian dysregulation of IL-17 immune cell producers. Thus, from a fundamental point of view, since 
we could not access to these tools, our study rather reveals diurnal – not circadian - oscillatory patterns. 
Given the important reports relating circadian and sleep perturbations with neurodegenerative diseases 
and the fact that increased levels of meningeal IL-17 contribute to the onset of AD (Brigas, H. et al., 
under review), we postulated that disturbances in diurnal oscillations could trigger the accumulation of 
this cytokine, thus contributing to disease progression. To tackle this question, we used a 3xTg-AD mice 
model that progressively reproduces the cognitive deficits and AD hallmarks225. These mice display 
abnormalities in their circadian rhythmicity, evidenced by a fragmented sleep-wake pattern with 
decreased activity levels during their active phase, increased activity during their resting phase226 and 
alteration of circadian clock transcription patterns in the SCN227. Unexpectedly, we found no oscillation 
of IL-17+ cells in the meninges of WT control mice in the two timepoints analysed, which were chosen 
based on the prediction that IL-17+ cells would have their bathyphase in the middle of the resting phase 
and acrophase in the middle of the active phase, as previously observed. We also observed that IL-17 
expression is reduced in the meninges and spleen during the night and no changes were found in the 
scLNs of both AD and their age- and sex-matched WT controls. The same phenotype was found for 
IFN-γ production. Several factors might have contributed to this phenomenon. Firstly, the genetic 
background of the mice used in both diurnal oscillatory experiments was different. To assess the diurnal 
oscillatory patterns in physiological contexts we used C57BL/6J mice, whereas in pathological contexts 
the AD mice and their recommended control have the C57BL/6-129SvJ background. Secondly, the sex 
of the mice was also different. In the first context we used males, while for the pathological implications 
the mice were females (according to Brigas, H. et al., under review). The circadian system response to 
light, its rhythm and amplitude has shown to be regulated by hormonal activation and therefore a sex 
dimorphism might explain the differential diurnal oscillation in IL-17+ cells228. Furthermore, a 
differential effect of sex hormones in the innate and adaptive immune systems is well described229. For 
instance, estrogen impairments on the negative selection of B cells promotes the maturation of auto-
reactive B cells230, enhancing female’s ability to produce antibodies231 and mount a more effective 
response to pathogens, but also increasing the predisposition autoimmunity disorders232. On the other 
hand, testosterone has immunosuppressive effects that translate in the downregulation of NK cell 
responses233 and reduced synthesis of TNFα and nitric oxide (NO) by DCs234, while increasing the anti-
inflammatory responses through IL-10 production235. Thirdly, the age of the mice was very different. 17 
wo mice were used in physiological conditions, while the AD mice and their controls had 7,5 mo. 
Interestingly, both healthy and pathological brain ageing are associated with cognitive decline associated 
with a functional weakening or disruption of the circadian patterns172 and a reduction of overall 
activity236. Therefore, one can postulate that circadian disruptions that occur during the natural ageing 
process might contribute to the development of neurodegenerative diseases. In fact, the C57BL/6-
129SvJ mice with 7,5 mo already show accumulated levels of IL-17+ cells in the meningeal spaces 
compared with the C57BL/6J indicative of a possible circadian disruption, although an impact of the 
genetic background and sex cannot be dismissed. Therefore, it would be interesting to analyse younger 




translate oscillatory changes. Finally, due to technical limitations, only two timepoints were analysed. 
We might be observing two points that do not have differences, thus dismissing a potential oscillatory 
pattern. A much extensive analysis with middle timepoints is required to draw further conclusions. 
As the transcriptomic analysis of cortices from sleep-deprived animals highlighted IL-17 regulated 
genes59, we next questioned whether sleep could influence IL-17 immune cell producers in the menin-
ges. Resorting to an anesthetic protocol shown to reproduce the main features of sleep185, we observed 
an increase in the number of leukocytes present in meninges. Since meningeal lymphatics are a clearing 
route for CSF content36,37, it is possible that during sleep meningeal lymphatic vessels act as a reservoir 
for different molecules and immune cells from the subarachnoid space and CSF41. Furthermore, we 
observed a decrease in the percentage of IL-17+ cells and IL-17 expression among total leukocytes in 
the anesthetized mice. Since the percentage of IFN-γ+ cells also decreased in the anesthetized mice, the 
effect of sleep on meninges might not be restricted to IL-17 immune cell producers. In turn, a global 
reduction in cytokine producers might be the consequence of the leukocyte influx observed during the 
night that creates a dilution effect. Interestingly, sleep restriction has been associated with increased 
levels of IL-1β, IL-6 and IL-17 in the blood237 and multiple pathways can mediate the relationship be-
tween sleep and immune function. Growth hormones and melatonin secreted during sleep promote the 
secretion of IL-1238,  while ACTH and cortisol release, along with the sympathetic tone, will affect the 
production of TH1 and TH2 cytokines239,240. However, anesthetized mice display a decrease in the per-
centage of IL-17+ cells specifically and exclusively in meninges, and not in the peripheral lymphoid 
organs, pointing at a local (rather than systemic) effect. Accordingly, the glymphatic flux increases dur-
ing sleep185 mediated by a circadian control196 and a dysfunction of both pathways contributes to the 
pathophysiology of various CNS diseases, including AD241. Additionally, sleep disturbances increase 
IL-6 levels and induce microglia activation specifically in the mouse hippocampus. These effects result 
in a selective impairment of hippocampus-dependent learning and memory through neuroinflammation 
in the hippocampus242. In this context, and accordingly to our results, sleep disturbances may trigger an 
accumulation of meningeal IL-17 levels that further contributes to the onset of cognitive deficits and 
impaired synaptic plasticity observed in AD mice. 
Of note, a possible effect of the anesthesia itself on IL-17 immune cell producers cannot be dismissed 
and might account for the differences observed. To control this variant, naturally sleeping mice should 
be used in further studies. Additionally, sleep deprivation models should also be included in the analysis. 
Last but not least, it is important to highlight that sleep and circadian rhythm are difficult to dissociated, 
thus we cannot exclude a combined impact of both parameters on the homeostasis of IL-17+ cells in the 
meninges. By instance, the adrenergic tone is known to be regulated by circadian cues, rising during the 
active phase of the animal and being reduced during sleep243. Additionally, the administration of keta-
mine/xylazine reduces norepinephrine levels, demonstrating a circadian independent mechanism185. 
Therefore, if adrenergic inputs would contribute to the increase in meningeal IL-17 during the active 
phase of the animal, a combined role of the circadian rhythms and sleep would be responsible for such 
outcome. Further experiments should envision this hypothesis and employ the methodologies referred 
above.  
Taken together, our results suggest that endogenous and environmental cues (stress, circadian rhythms 
and sleep) are valuable candidates to control the homeostasis of IL-17-producing immune cells in the 
meninges and open new lines of fundamental investigation. Importantly, all these factors are implicated 
in higher mental processes and neurodegenerative disorders. The modulation of these cues might give 
further insight into the cellular and molecular mechanisms that underlie learning and memory, with a 
biomedical potential for neurodegenerative diseases.  
To conclude, this exploratory study is an important step towards the characterization of meningeal im-
mune subset biology and laid the groundwork to advance our understanding of the mechanisms under-
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Figure S1 – Accumulation of IL-17+ cells in the meninges at the onset of cognitive deficits of 3xTg-AD mice. Meningeal 
cell suspensions were prepared from 2-3, 5-6 and 8-9-month-old WT and 3xTg-AD female mice. Cells were analysed for the 
expression of surface (CD45, CD3, TCRδ and CD4) and intracellular (IL-17) markers. Live cells were gated using LiveDead 
Fixable Viability Dye. (A) Representative contour plots displaying IL-17+ cells among live CD45+ cells in 5-6 month-old WT 
and 3xTg-AD mice (left), and their quantification through the disease progression (right). (B) Pie charts indicating the 
proportion of each cell subsets to the IL-17+ immune cell population in the indicated organs. Pie charts display the mean values 
of data from 1-3 independent experiments with n=4-11 individual measures obtained by pooling meningeal spaces of 2 mice, 






Figure S2 – Putative accumulation of IL-17+ cells in the meninges of Thy1-αSyn PD mice. Meningeal cell suspensions 
were prepared from 6-month-old WT and Thy1-αSyn male mice. Cells were analysed for the expression of surface (CD45, 
CD19, CD3, TCRδ, CD4 and CD8) and intracellular (IL-17) markers. (A) Representative contour plots displaying IL-17+ cells 
among live CD45+ cells in WT and PD mice (left), and their quantification (right). (B) Pie charts indicating the proportion of 
each cell subsets to the IL-17+ immune cell population in the indicated organs. Live cells were gated using LiveDead Fixable 




























































Figure S3 – Gating strategy used for the identification of immune cell subsets and their respective IL-17 and IFN-γ 
production by flow cytometry. (A) The identification live leukocytes was performed through the application of a time gating 
among total cells, followed by leukocyte selection, doublets exclusion, and the selection of CD45+ among the LiveDead 
negative subset (B) Among live CD45+ cells, CD3- CD19- and CD3+ CD19- immune cell subsets were identified. Within CD3+ 
CD19-, CD3+ TCRδ+ cells were identified. IL-17 and IFN-γ production was assessed within CD3- CD19- cells and CD3+ 
TCRδ+ cells. (C) Among live CD3+ TCRδ+ cells, CD3+ CD4+, CD3+ CD8+, and CD3+ CD4- CD8- immune cell subsets were 







Figure S4 – In vitro dexamethasone treatment of γδ T cells inhibits the survival of IFNγ+ cells at high dose. Total γδ T 
cells were sorted by FACS from the peripheral lymph nodes (superficial cervical, axillary, brachial and inguinal LN) and the 
spleen of WT C57BL/6J mice. Cells were cultured in presence of anti-CD3e antibody (3 μg/ml, plate bound), IL-1β (10 ng/ml), 
IL-23 (10 ng/ml) and IL-7 (40 ng/ml); and treated with a dexamethasone (DEX) or the vehicle solution. After 72 hours of 
culture with different concentrations of dexamethasone (10-10 M, 10-8 M and 10-6 M), cells were analysed by flow cytometry 
for the expression of surface (CD3, TCRδ) and intracellular (IFNγ) markers. Live cells were gated using LiveDead Fixable 
Viability Dye. (A) Representative dot plots of two independent experiments displaying the IFNγ + cells among 10000 live γδ 
T cells from indicated samples (left), their quantification (middle), and the ratio of the geomean fluorescence intensity (gMFI) 
of dexamethasone- or vehicle-treated γδ T cell (right). Mean ± SD. 
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Figure S5 – In vivo dexamethasone administration does not alter meningeal IFN-γ+ immune cells homeostasis. Cell 
suspensions were prepared from the indicated organs of dexamethasone- or vehicle-treated C57BL/6J WT mice, and analysed 
by flow cytometry for the expression of surface (CD45, CD19, CD3, TCRδ, CD4 and CD8) and intracellular (IFNγ) markers. 
Live cells were gated using LiveDead Fixable Viability Dye. (A) Smoothened dot plots depicting IFNγ+ cells among 900 live 
CD45+ cells isolated from meninges of dexamethasone or vehicle-treated animals (left), their quantification (middle), and their 
geomean fluorescence intensity (gMFI) (right). The same quantifications were made for the scLNs in (B) and spleen cell 









Figure S6 – In vivo dexamethasone administration drives the overexpression of IL-7 receptor by γδ, CD4+ and CD8+ T 
cells. Cell suspensions were prepared from superficial cervical lymph nodes (scLNs) of dexamethasone- or vehicle-treated 
C57BL/6J WT mice, and analysed by flow cytometry for the surface (CD3, TCRδ, CD4, CD8, IL-7R) markers. Live cells were 
gated using LiveDead Fixable Viability Dye. (A) Representative histograms displaying the IL-7R expression by the indicated 
cell subsets isolated from dexamethasone- (empty dark) or vehicle- (grey-filled) treated animals. (B) Geomean fluorescence 
intensity (gMFI) for the associated IL-7R signal of CD3+γδ T cell, CD3+CD4+ T cell, CD3+CD8+ T cell, CD3+CD4- CD8- T 

































































































































































































Figure S7 – The proportion of IFN-γ+ immune cells exhibit a diurnal oscillatory pattern in the meninges of wild type 
mice. Cell suspensions were prepared from the indicated organs of WT C57BL/6J mice sacrificed at ZT7, ZT15, and ZT23 
(normal light:dark cycle). Cells were analysed by flow cytometry for the expression of surface (CD45, CD19, CD3, TCRδ, 
CD4 and CD8) and intracellular (IFNγ) markers. Live cells were gated using LiveDead Fixable Viability Dye. (A) Smoothened 
dot plots depicting IFNγ+ cells among 2000 live CD45+ cells isolated from meninges at the indicated ZT (left), their 
quantification (middle), and their geomean fluorescence intensity (gMFI) (right). The same quantifications were made for the 
(B) scLNs and (C) spleen cell suspensions. Data are from 3 independent experiments, with n=3 individual measures per 
timepoint for meninges (obtained by pooling meningeal spaces of 3-4 mice), and n=3 mice per timepoint for scLNs or spleen. 













Figure S8 – The proportion of IFNγ+ immune cells in the meninges of a 3xTg-AD mice do not display a diurnal 
oscillatory pattern. Cell suspensions were prepared from the indicated organs of 7-month-old WT and 3xTg-AD C57BL/6J-
129SvJ female mice sacrificed at ZT7 and ZT19 (normal light:dark cycle). Cells were analysed by flow cytometry for the 
expression of surface (CD45, CD19, CD3, TCRδ, CD4 and CD8) and intracellular (IFNγ) markers. Live cells were gated using 
LiveDead Fixable Viability Dye. (A) Smoothened dot plots depicting IFNγ+ cells among 500 live CD45+ cells isolated from 
meninges at the indicated ZT (left), their quantification (middle), and their geomean fluorescence intensity (gMFI) (right). The 
same quantifications were made for the scLNs in (B) and spleen cell suspensions (C). Data are from 1 independent experiment, 






















































































































































































































































































































Figure S9 – Meningeal IFN-γ+ immune cells proportion is reduced after a ketamine/xylazine-induced anesthesia. Cell 
suspensions were prepared from the indicated organs of anesthetized (K/X-treated) or awake (vehicle-treated) WT C57BL/6J 
mice. Cells were analysed by flow cytometry for the expression of surface (CD45, CD19, CD3, TCRδ, CD4 and CD8) and 
intracellular (IFNγ) markers. Live cells were gated using LiveDead Fixable Viability Dye. (A) Smoothened dot plots depicting 
IL-17+ cells among 1000 live CD45+ cells isolated from meninges of the anesthetized or awake animals (left), their 
quantification (middle), and their geomean fluorescence intensity (gMFI) (right). The same quantifications were made for the 
(B) scLN and (C) spleen cell suspensions. Data are from 1 independent experiment, n=2-3 mice per group. Mean ± SD. 
Table S1 - List of antibodies used for FACS analysis. 
Specificiy Clone Fluorochrome Origin 
anti-mouse CD3e 145-2C11 PE-Cy7 Biolegend 
anti-mouse CD3e 17A2 BV711 Biolegend 
anti-mouse CD3e 145.2C11 PerCp/Cy5.5 Biolegend 
anti-mouse CD45 30-F11 BV510 Biolegend 
anti-mouse CD4 GK1.5 PerCp/Cy5.5 Biolegend 
anti-mouse CD4 GK1.5 PE-Cy7 ThermoFischer 
anti-mouse CD8 53-6.7 PerCp/Cy-5.5 Biolegend 
anti-mouse CD8 53-6.7 BV711 Biolegend 
anti-mouse CD8 53-6.7 SB702 ThermoFischer 
anti-mouse TCRγ/δ GL3 APC ThermoFischer 
anti-mouse TCRγ/δ GL3 BV421 Biolegend 
anti-mouse TCRγ/δ GL3 PE Biolegend 
anti-mouse CD19 6D5 BV605 Biolegend 
anti-mouse IL-17A TC11-18H10 FITC Biolegend 
anti-mouse IL-17A TC11-18H10 APC Biolegend 
anti-mouse IFN-γ XMG12 PE Biolegend 
anti-mouse IFN-γ XMG1.2 APC Biolegend 
Anti-mouse RORγt B2D APC ThermoFisher 
Anti-mouse Ki67 16A8 BV605 Biolegend 
Anti-mouse IL-7Rα A7R34 PE Biolegend 
Anti-mouse CD44 IM7 BV711 Biolegend 
Anti-mouse CD45RB C363.16A PE Biolegend 
Anti-mouse CD27 LG.3A10 PE BD Biosciences 
Anti-mouse CD27 LG.7F9 PE-Cy7 ThermoFisher 
Anti-mouse CD25 PC61.5 APC ThermoFisher 
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